



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/47, A61K 38/17		A2	(11) International Publication Number: WO 98/55614
(21) International Application Number: PCT/US98/11210		(43) International Publication Date: 10 December 1998 (10.12.98)	
(22) International Filing Date: 1 June 1998 (01.06.98)		(72) Inventors: JACOBS, Kenneth; 151 Beaumont Street, Newton, MA 02160 (US). McCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LAVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US). RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US). SPAULDING, Vikki; 11 Meadowbank Road, Billerica, MA 01821 (US). AGOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US). HOWES, Steven, H.; Apartment 2, 44 Chester Street, Somerville, MA 02144 (US). FECHTEL, Kim; 46 Marion Road, Arlington, MA 02174 (US).	
(30) Priority Data: 08/868,899 4 June 1997 (04.06.97) US 08/868,898 4 June 1997 (04.06.97) US 08/869,192 4 June 1997 (04.06.97) US 08/869,191 4 June 1997 (04.06.97) US 08/869,193 4 June 1997 (04.06.97) US 08/868,697 4 June 1997 (04.06.97) US 08/868,698 4 June 1997 (04.06.97) US 08/868,900 4 June 1997 (04.06.97) US 08/868,696 4 June 1997 (04.06.97) US 08/869,194 4 June 1997 (04.06.97) US 09/087,255 29 May 1998 (29.05.98) US		(74) Agent: SPRUNGER, Suzanne, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).	
(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	
(54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM			
(57) Abstract Polynucleotides and the proteins encoded thereby are disclosed.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	JP	Japan	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	KE	Kenya	NL	Netherlands	VN	Viet Nam
CG	Congo	KG	Kyrgyzstan	NO	Norway	YU	Yugoslavia
CH	Switzerland	KP	Democratic People's Republic of Korea	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KR	Republic of Korea	PL	Poland		
CM	Cameroon	KZ	Kazakhstan	PT	Portugal		
CN	China	LC	Saint Lucia	RO	Romania		
CU	Cuba	LI	Liechtenstein	RU	Russian Federation		
CZ	Czech Republic	LK	Sri Lanka	SD	Sudan		
DE	Germany	LR	Liberia	SE	Sweden		
DK	Denmark			SG	Singapore		
EE	Estonia						

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

5 This application is a continuation-in-part of the following applications:

- (1) Ser. No. 60/XXX,XXX (converted to a provisional application from non-provisional application Ser. No. 08/868,899), filed June 4, 1997;
- (2) Ser. No. 60/XXX,XXX (converted to a provisional application from non-provisional application Ser. No. 08/868,898), filed June 4, 1997;
- 10 (3) Ser. No. 60/XXX,XXX (converted to a provisional application from non-provisional application Ser. No. 08/869,192), filed June 4, 1997;
- (4) Ser. No. 60/XXX,XXX (converted to a provisional application from non-provisional application Ser. No. 08/869,191), filed June 4, 1997;
- (5) Ser. No. 60/XXX,XXX (converted to a provisional application from non-provisional application Ser. No. 08/869,193), filed June 4, 1997;
- 15 (6) Ser. No. 60/XXX,XXX (converted to a provisional application from non-provisional application Ser. No. 08/868,697), filed June 4, 1997;
- (7) Ser. No. 60/XXX,XXX (converted to a provisional application from non-provisional application Ser. No. 08/868,698), filed June 4, 1997;
- 20 (8) Ser. No. 60/XXX,XXX (converted to a provisional application from non-provisional application Ser. No. 08/868,900), filed June 4, 1997;
- (9) Ser. No. 60/XXX,XXX (converted to a provisional application from non-provisional application Ser. No. 08/868,696), filed June 4, 1997;
- (10) Ser. No. 60/XXX,XXX (converted to a provisional application from non-provisional application Ser. No. 08/869,194), filed June 4, 1997;
- 25 all of which are incorporated by reference herein.

30

35

40

FIELD OF THE INVENTION

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

5

BACKGROUND OF THE INVENTION

Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

10
15
20

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

25

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 266 to nucleotide 1651;

30

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 521 to nucleotide 1651;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 335 to nucleotide 634;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone as294_3 deposited under accession number ATCC 98444;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone as294_3 deposited under accession number ATCC 98444;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone as294_3 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone as294_3 deposited under accession number ATCC 98444;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 266 to nucleotide 1651; the nucleotide sequence of SEQ ID NO:1 from nucleotide 521 to nucleotide 1651; the nucleotide sequence of SEQ ID NO:1 from nucleotide 335 to nucleotide 634; the nucleotide sequence of the full-length protein coding sequence of clone as294_3 deposited under accession number ATCC 98444; or the nucleotide sequence of a mature protein coding sequence of clone as294_3 deposited under accession number ATCC 98444. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone as294_3 deposited under accession number ATCC 98444. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 123. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2

having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence
5 from amino acid 226 to amino acid 235 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group
10 consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
 - (b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 123;
 - (c) fragments of the amino acid sequence of SEQ ID NO:2 comprising
15 eight consecutive amino acids of SEQ ID NO:2; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone as294_3 deposited under accession number ATCC 98444;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2 or the amino acid sequence
20 of SEQ ID NO:2 from amino acid 1 to amino acid 123. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID
25 NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 226 to amino acid 235 of SEQ ID NO:2.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
30 NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 262 to nucleotide 3096;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 1118 to nucleotide 1527;

- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone aw92_1 deposited under accession number ATCC 98444;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone aw92_1 deposited under accession number ATCC 98444;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone aw92_1 deposited under accession number ATCC 98444;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone aw92_1 deposited under accession number ATCC 98444;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 262 to nucleotide 3096; the nucleotide sequence of SEQ ID NO:3 from nucleotide 1118 to nucleotide 1527; the nucleotide sequence of the full-length protein coding sequence of clone aw92_1 deposited under accession number ATCC 98444; or the nucleotide sequence of a mature protein coding sequence of clone aw92_1 deposited under accession number ATCC 98444. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone aw92_1 deposited under accession number ATCC 98444. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 287 to amino acid 422. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably

twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 467 to amino acid 476 of SEQ ID NO:4.

5 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:4;
(b) the amino acid sequence of SEQ ID NO:4 from amino acid 287 to amino acid 422;
(c) fragments of the amino acid sequence of SEQ ID NO:4 comprising eight consecutive amino acids of SEQ ID NO:4; and
15 (d) the amino acid sequence encoded by the cDNA insert of clone aw92_1 deposited under accession number ATCC 98444;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4 or the amino acid sequence of SEQ ID NO:4 from amino acid 287 to amino acid 422. In further preferred
20 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence
25 from amino acid 467 to amino acid 476 of SEQ ID NO:4.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
30 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 612 to nucleotide 806;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 744 to nucleotide 806;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 1 to nucleotide 794;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bd316_2 deposited under accession number ATCC 98444;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bd316_2 deposited under accession number ATCC 98444;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bd316_2 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bd316_2 deposited under accession number ATCC 98444;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:6;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 612 to nucleotide 806; the nucleotide sequence of SEQ ID NO:5 from nucleotide 744 to nucleotide 806; the nucleotide sequence of SEQ ID NO:5 from nucleotide 1 to nucleotide 794; the nucleotide sequence of the full-length protein coding sequence of clone bd316_2 deposited under accession number ATCC 98444; or the nucleotide sequence of a mature protein coding sequence of clone bd316_2 deposited under accession number ATCC 98444. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bd316_2 deposited under accession number ATCC 98444. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 61.

In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:6, or a
5 polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 27 to amino acid 36 of SEQ ID NO:6.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.

10 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
 - (b) the amino acid sequence of SEQ ID NO:6 from amino acid 1 to
15 amino acid 61;
 - (c) fragments of the amino acid sequence of SEQ ID NO:6 comprising eight consecutive amino acids of SEQ ID NO:6; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone
20 bd316_2 deposited under accession number ATCC 98444;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6 or the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 61. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising
25 eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 27 to amino acid 36 of SEQ ID NO:6.

In one embodiment, the present invention provides a composition comprising an
30 isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 7 to nucleotide 300;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 1 to nucleotide 363;

5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bk130_4 deposited under accession number ATCC 98444;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bk130_4 deposited under accession number ATCC 98444;

10 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bk130_4 deposited under accession number ATCC 98444;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bk130_4 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;

15 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:8;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

20 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 7 to nucleotide 300; the nucleotide sequence of SEQ ID NO:7 from nucleotide 1 to nucleotide 363; the nucleotide sequence of the full-length protein coding sequence of clone bk130_4 deposited under accession number ATCC 98444; or the nucleotide sequence of a mature protein coding sequence of clone bk130_4 deposited under accession number ATCC 98444. In other preferred embodiments, the
30 polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bk130_4 deposited under accession number ATCC 98444. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most

preferably thirty) consecutive amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 44 to amino acid 53 of SEQ ID NO:8.

5 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:8;
(b) fragments of the amino acid sequence of SEQ ID NO:8 comprising eight consecutive amino acids of SEQ ID NO:8; and
(c) the amino acid sequence encoded by the cDNA insert of clone bk130_4 deposited under accession number ATCC 98444;

15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino
20 acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 44 to amino acid 53 of SEQ ID NO:8.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 52 to nucleotide 1863;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
30 NO:9 from nucleotide 1219 to nucleotide 1863;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 1099 to nucleotide 1743;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bv131_5 deposited under accession number ATCC 98444;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bv131_5 deposited under accession number ATCC 98444;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bv131_5 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bv131_5 deposited under accession number ATCC 98444;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:10;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 52 to nucleotide 1863; the nucleotide sequence of SEQ ID NO:9 from nucleotide 1219 to nucleotide 1863; the nucleotide sequence of SEQ ID NO:9 from nucleotide 1099 to nucleotide 1743; the nucleotide sequence of the full-length protein coding sequence of clone bv131_5 deposited under accession number ATCC 98444; or the nucleotide sequence of a mature protein coding sequence of clone bv131_5 deposited under accession number ATCC 98444. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bv131_5 deposited under accession number ATCC 98444. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10 from amino acid 430 to amino acid 564. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10

having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid
 5 sequence from amino acid 297 to amino acid 306 of SEQ ID NO:10.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group
 10 consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
 - (b) the amino acid sequence of SEQ ID NO:10 from amino acid 430 to amino acid 564;
 - (c) fragments of the amino acid sequence of SEQ ID NO:10 comprising
 15 eight consecutive amino acids of SEQ ID NO:10; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone bv131_5 deposited under accession number ATCC 98444;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10 or the amino acid sequence
 20 of SEQ ID NO:10 from amino acid 430 to amino acid 564. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid
 25 SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 297 to amino acid 306 of SEQ ID NO:10.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
 30 NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 67 to nucleotide 690;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 1 to nucleotide 576;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bv227_1 deposited under accession number ATCC 98444;

5 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bv227_1 deposited under accession number ATCC 98444;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bv227_1 deposited under accession number ATCC 98444;

10 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bv227_1 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;

15 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:12;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

20 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 67 to nucleotide 690; the nucleotide sequence of SEQ ID NO:11 from nucleotide 1 to nucleotide 576; the nucleotide sequence of the full-length protein coding sequence of clone bv227_1 deposited under accession number ATCC 98444; or the
25 nucleotide sequence of a mature protein coding sequence of clone bv227_1 deposited under accession number ATCC 98444. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bv227_1 deposited under accession number ATCC 98444. In yet other preferred
30 embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 170. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably

twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:12.

5 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:12;
(b) the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 170;
(c) fragments of the amino acid sequence of SEQ ID NO:12 comprising eight consecutive amino acids of SEQ ID NO:12; and
15 (d) the amino acid sequence encoded by the cDNA insert of clone bv227_1 deposited under accession number ATCC 98444;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12 or the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 170. In further preferred embodiments,
20 the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from
25 amino acid 99 to amino acid 108 of SEQ ID NO:12.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
30 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 657 to nucleotide 1469;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 678 to nucleotide 1103;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cd265_11 deposited under accession number ATCC 98444;

5 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cd265_11 deposited under accession number ATCC 98444;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cd265_11 deposited under accession number ATCC 98444;

10 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cd265_11 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;

15 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:14;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

20 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 657 to nucleotide 1469; the nucleotide sequence of SEQ ID NO:13 from nucleotide 678 to nucleotide 1103; the nucleotide sequence of the full-length protein coding sequence of clone cd265_11 deposited under accession number ATCC 98444; or the
25 nucleotide sequence of a mature protein coding sequence of clone cd265_11 deposited under accession number ATCC 98444. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cd265_11 deposited under accession number ATCC 98444. In yet other preferred
30 embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14 from amino acid 8 to amino acid 149. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably

twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 130 to amino acid 139 of SEQ ID NO:14.

5 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:14;
(b) the amino acid sequence of SEQ ID NO:14 from amino acid 8 to amino acid 149;
(c) fragments of the amino acid sequence of SEQ ID NO:14 comprising eight consecutive amino acids of SEQ ID NO:14; and
15 (d) the amino acid sequence encoded by the cDNA insert of clone cd265_11 deposited under accession number ATCC 98444;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14 or the amino acid sequence of SEQ ID NO:14 from amino acid 8 to amino acid 149. In further preferred embodiments,
20 the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from
25 amino acid 130 to amino acid 139 of SEQ ID NO:14.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
30 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 261 to nucleotide 896;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 330 to nucleotide 896;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 1 to nucleotide 515;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ej265_4 deposited under accession number ATCC 98444;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ej265_4 deposited under accession number ATCC 98444;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ej265_4 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ej265_4 deposited under accession number ATCC 98444;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:16;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 261 to nucleotide 896; the nucleotide sequence of SEQ ID NO:15 from nucleotide 330 to nucleotide 896; the nucleotide sequence of SEQ ID NO:15 from nucleotide 1 to nucleotide 515; the nucleotide sequence of the full-length protein coding sequence of clone ej265_4 deposited under accession number ATCC 98444; or the nucleotide sequence of a mature protein coding sequence of clone ej265_4 deposited under accession number ATCC 98444. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ej265_4 deposited under accession number ATCC 98444. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16 from amino acid 1 to amino acid 85. In further preferred

embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:16, or a polynucleotide encoding
5 a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID NO:16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

10 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:16;
 - (b) the amino acid sequence of SEQ ID NO:16 from amino acid 1 to
15 amino acid 85;
 - (c) fragments of the amino acid sequence of SEQ ID NO:16 comprising eight consecutive amino acids of SEQ ID NO:16; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone ej265_4 deposited under accession number ATCC 98444;
- 20 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16 or the amino acid sequence of SEQ ID NO:16 from amino acid 1 to amino acid 85. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising
25 eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID NO:16.

In one embodiment, the present invention provides a composition comprising an
30 isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 946 to nucleotide 2232;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 1336 to nucleotide 1853;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ey29_8 deposited under accession number ATCC 98444;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ey29_8 deposited under accession number ATCC 98444;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ey29_8 deposited under accession number ATCC 98444;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ey29_8 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:18;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 946 to nucleotide 2232; the nucleotide sequence of SEQ ID NO:17 from nucleotide 1336 to nucleotide 1853; the nucleotide sequence of the full-length protein coding sequence of clone ey29_8 deposited under accession number ATCC 98444; or the nucleotide sequence of a mature protein coding sequence of clone ey29_8 deposited under accession number ATCC 98444. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ey29_8 deposited under accession number ATCC 98444. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18 from amino acid 138 to amino acid 302. In further preferred embodiments, the present invention provides a polynucleotide encoding a

protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 209 to amino acid 218 of SEQ ID NO:18.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
 - (b) the amino acid sequence of SEQ ID NO:18 from amino acid 138 to amino acid 302;
 - (c) fragments of the amino acid sequence of SEQ ID NO:18 comprising eight consecutive amino acids of SEQ ID NO:18; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone ey29_8 deposited under accession number ATCC 98444;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:18 or the amino acid sequence of SEQ ID NO:18 from amino acid 138 to amino acid 302. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 209 to amino acid 218 of SEQ ID NO:18.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 2588 to nucleotide 3439;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 3005 to nucleotide 3502;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone gm114_10 deposited under accession number ATCC 98444;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone gm114_10 deposited under accession number ATCC 98444;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone gm114_10 deposited under accession number ATCC 98444;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone gm114_10 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:20;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:19 from nucleotide 2588 to nucleotide 3439; the nucleotide sequence of SEQ ID NO:19 from nucleotide 3005 to nucleotide 3502; the nucleotide sequence of the full-length protein coding sequence of clone gm114_10 deposited under accession number ATCC 98444; or the nucleotide sequence of a mature protein coding sequence of clone gm114_10 deposited under accession number ATCC 98444. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone gm114_10 deposited under accession number ATCC 98444. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20 from amino acid 145 to amino acid 284. In further preferred embodiments, the present invention provides a

polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 137 to amino acid 146 of SEQ ID NO:20.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:19.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:20;
 - (b) the amino acid sequence of SEQ ID NO:20 from amino acid 145 to amino acid 284;
 - (c) fragments of the amino acid sequence of SEQ ID NO:20 comprising eight consecutive amino acids of SEQ ID NO:20; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone gm114_10 deposited under accession number ATCC 98444;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:20 or the amino acid sequence of SEQ ID NO:20 from amino acid 145 to amino acid 284. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 137 to amino acid 146 of SEQ ID NO:20.

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

(a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and

(b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

DETAILED DESCRIPTION

ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell

in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

Clone "as294_3"

5 A polynucleotide of the present invention has been identified as clone "as294_3". as294_3 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. as294_3 is a full-length clone,
10 including the entire coding sequence of a secreted protein (also referred to herein as "as294_3 protein").

The nucleotide sequence of as294_3 as presently determined is reported in SEQ ID NO:1. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the as294_3 protein corresponding to the foregoing nucleotide
15 sequence is reported in SEQ ID NO:2. Amino acids 73 to 85 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 86, or are a transmembrane domain. Amino acids 102 to 114 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 115, or are a transmembrane domain.

20 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone as294_3 should be approximately 1900 bp.

The nucleotide sequence disclosed herein for as294_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. as294_3 demonstrated at least some similarity with sequences
25 identified as AA206777 (zq80d04.s1 Stratagene hNT neuron (#937233) Homo sapiens cDNA clone 647911 3'), AA206905 (zq80d04.r1 Stratagene hNT neuron (#937233) Homo sapiens cDNA clone 647911 5'), AA280222 (zt04c05.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 712136 5'), H19869 (yn57a08.s1 Homo sapiens cDNA clone 172502 3'), H24249 (ym50h12.r1 Homo sapiens cDNA clone 52050 5'), N44936 (yy34f11.r1
30 Homo sapiens cDNA clone 273165 5'), R15379 (yf90f03.r1 Homo sapiens cDNA clone 29694 5'), R43727 (yg20c11.s1 Homo sapiens cDNA clone 32810 3'), R88673 (ym93f09.r1 Homo sapiens cDNA clone 166505 5'), T21648 (Human gene signature HUMGS03085), T80165 (5p IMAGE clone), and Z99260 (GenPept S. pombe hypothetical

protein). The predicted amino acid sequence disclosed herein for as294_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted as294_3 protein demonstrated at least some similarity to sequences identified as X73434 (KAP5.4 keratin protein [Ovis aries]) and Z99260 (hypothetical protein [Schizosaccharomyces pombe]). Based upon sequence similarity, as294_3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the as294_3 protein sequence, centered around amino acids 105, 228, and 307 of SEQ ID NO:2, respectively.

10

Clone "aw92_1"

A polynucleotide of the present invention has been identified as clone "aw92_1". aw92_1 was isolated from a cDNA library of human adult ovary (comprising untreated tissue and tissue treated with retinoic acid and activin), using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. aw92_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "aw92_1 protein").

The nucleotide sequence of aw92_1 as presently determined is reported in SEQ ID NO:3. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the aw92_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone aw92_1 should be approximately 2950 bp.

The nucleotide sequence disclosed herein for aw92_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. aw92_1 demonstrated at least some similarity with sequences identified as AF021936 (Rattus norvegicus myotonic dystrophy kinase-related Cdc42-binding kinase MRCK-beta (MRCK-beta) mRNA, complete CDs, GP2736153), T23529 (seq3368 Homo sapiens cDNA clone Hy18-Charon40-cDNA-247 3'), U59305 (Human ser-thr protein kinase PK428 mRNA, complete cds), W16524 (zb15h09.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 302177 5' similar to PIR A42101 A42101 protein kinase homolog - human; contains element MER22 repetitive element), and

X69292 (H.sapiens mRNA for smooth muscle myosin). The predicted amino acid sequence disclosed herein for aw92_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted aw92_1 protein demonstrated at least some similarity to sequences identified as L03534 (ENHMHCAAX_1 myosin heavy chain [Entamoeba histolytica]), R41000 (Human brain cDNA clone C28 protein kinase), U59305 (ser-thr protein kinase PK428 [Homo sapiens]), W02258 (Nucleolar/endosomal auto-antigen p162), and X03740 (myosin heavy chain (876 AA) [Homo sapiens]). Based upon sequence similarity, aw92_1 proteins and each similar protein or peptide may share at least some activity.

Clone "bd316_2"

A polynucleotide of the present invention has been identified as clone "bd316_2". bd316_2 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bd316_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bd316_2 protein").

The nucleotide sequence of bd316_2 as presently determined is reported in SEQ ID NO:5. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bd316_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6. Amino acids 32 to 44 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 45, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bd316_2 should be approximately 1200 bp.

The nucleotide sequence disclosed herein for bd316_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bd316_2 demonstrated at least some similarity with sequences identified as AA234339 (zr72d12.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 668951 3'), L05367 (Human oligodendrocyte myelin glycoprotein (OMG) exons 1-2; neurofibromatosis 1 (NF1) exons 28-49; ecotropic viral integration site 2B (EVI2B) exons 1-2; ecotropic viral integration site 2A (EVI2A) exons 1-2; adenylate kinase (AK3) exons

1-2), N30778 (yw74h08.s1 Homo sapiens cDNA clone 258015 3' similar to gbM73048IHUMU3AAAA Human U3 small nuclear RNA (rRNA); contains MER12.t1 MER12 repetitive element), U52195 (Human desmoglein 3 gene, promoter region), U60822 (Human dystrophin (DMD) gene, exons 7, 8 and 9, and partial cds), X85184
 5 (R.norvegicus mRNA for ras-related GTPase, ragB), and X90530 (H.sapiens mRNA for ragB protein). Based upon sequence similarity, bd316_2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the bd316_2 protein sequence centered around amino acid 35 of SEQ ID NO:6.

10

Clone "bk130_4"

A polynucleotide of the present invention has been identified as clone "bk130_4". bk130_4 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was
 15 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bk130_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bk130_4 protein").

The nucleotide sequence of bk130_4 as presently determined is reported in SEQ
 20 ID NO:7. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bk130_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bk130_4 should be approximately 550 bp.

25 The nucleotide sequence disclosed herein for bk130_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bk130_4 demonstrated at least some similarity with sequences identified as AA009736 (ze82e04.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 365502 3'), AA112971 (zn59b09.r1 Stratagene muscle 937209 Homo sapiens cDNA
 30 clone 562457 5'), AA196543 (zq08e12.s1 Stratagene muscle 937209 Homo sapiens cDNA clone 629134 3'), AA196677 (zq08e10.r1 Stratagene muscle 937209 Homo sapiens cDNA clone 629130 5'), AA232667 (zr74e10.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 669162 3'), H26737 (yl14f12.r1 Homo sapiens cDNA clone 158255 5'), H44642

(yp20a08.r1 Homo sapiens cDNA clone 187958 5'), and W72771 (zd77c12.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 346678 5'). The predicted amino acid sequence disclosed herein for bk130_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bk130_4 protein demonstrated at least some similarity to sequences identified as L11647 (glycogen branching enzyme [Streptomyces aureofaciens]), L23651 (homology with C. elegans cuticle collagen; putative [Caenorhabditis elegans]), W03740 (rchd528 gene product), and Z29095 (R10E11.1 [Caenorhabditis elegans]). Based upon sequence similarity, bk130_4 proteins and each similar protein or peptide may share at least some activity.

Clone "bv131_5"

A polynucleotide of the present invention has been identified as clone "bv131_5". bv131_5 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bv131_5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bv131_5 protein").

The nucleotide sequence of bv131_5 as presently determined is reported in SEQ ID NO:9. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bv131_5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10. Amino acids 377 to 389 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 390, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bv131_5 should be approximately 2900 bp.

The nucleotide sequence disclosed herein for bv131_5 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bv131_5 demonstrated at least some similarity with sequences identified as AA233510 (zr29h03.r1 Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone 664853 5' similar to TR:G1151007 G1151007 ATP DEPENDENT PERMEASE), H24176 (ym55e05.r1 Homo sapiens cDNA clone 52176 5'), R13832 (yf65a02.r1 Homo sapiens cDNA clone 26986 5' similar to SP:ADP1_YEAST P25371

PROBABLE ATP-DEPENDENT PERMEASE), R16423 (yf40d03.r1 Homo sapiens cDNA clone 129317 5'), T00880 (Human cisplatin resistance gene cDNA62), T12316 (Replicable and transcriptionally active plasmid), T78871 (yd83b08.s1 Homo sapiens cDNA clone 114807 3'), U66681 (Human clone EST157481 ATP-binding cassette transporter mRNA sequence), and V00710 (Human mitochondrial genes for several tRNAs (Phe, Val, Leu) and 12S and 16S ribosomal RNAs). The predicted amino acid sequence disclosed herein for bv131_5 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bv131_5 protein demonstrated at least some similarity to sequences identified as U34919 (white homolog [Homo sapiens]), Z48745 (murine ABC8), and Z49821 (putative ABC transporter [Saccharomyces cerevisiae]). Based upon sequence similarity, bv131_5 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five additional potential transmembrane domains within the bv131_5 protein sequence, centered around amino acids 354, 439, 463, 494 and 588 of SEQ ID NO:10, respectively.

Clone "bv227_1"

A polynucleotide of the present invention has been identified as clone "bv227_1". bv227_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bv227_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bv227_1 protein").

The nucleotide sequence of bv227_1 as presently determined is reported in SEQ ID NO:11. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bv227_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Amino acids 45 to 57 of SEQ ID NO:12 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 58, or are a transmembrane domain. Another potential bv227_1 reading frame and predicted amino acid sequence is encoded by basepairs 921 to 2294 of SEQ ID NO:11 and is reported in SEQ ID NO:31. A frameshift in the nucleotide sequence of SEQ ID NO:11 between about nucleotide 664 to about nucleotide 690 could extend the

reading frame of SEQ ID NO:31 to form a reading frame extending from position 666 to 2294 of SEQ ID NO:11 and encoding the amino acid sequence reported in SEQ ID NO:32.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bv227_1 should be approximately 3300 bp.

5 The nucleotide sequence disclosed herein for bv227_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bv227_1 demonstrated at least some similarity with sequences identified as AA368932 (EST80282 Placenta I Homo sapiens cDNA similar to similar to beta-1-glycoprotein PSGGA, pregnancy-specific), D60272 (Human fetal brain cDNA
10 3'-end GEN-095A07), M58526 (Human alpha-5 collagen type IV (COL4A5) mRNA, 3' end), Q64556 (Human collagen (Type V) coding sequence), R74388 (y157f11.s1 Homo sapiens cDNA clone 143373 3'), and T67066 (Human alpha3(IX) collagen cDNA). The predicted amino acid sequences disclosed herein for bv227_1 were searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
15 The predicted bv227_1 proteins of SEQ ID NO:31 and SEQ ID NO:32 demonstrated at least some similarity to sequences identified as S57132 (type XVI collagen alpha 1 chain, alpha 1 (XVI) [human, placenta, Peptide Partial, 1186 aa] [Homo sapiens]) and W07539 (Collagen like protein (CLP)). Based upon sequence similarity, bv227_1 proteins and each similar protein or peptide may share at least some activity.

20

Clone "cd265_11"

A polynucleotide of the present invention has been identified as clone "cd265_11". cd265_11 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was
25 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cd265_11 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "cd265_11 protein").

The nucleotide sequence of cd265_11 as presently determined is reported in SEQ
30 ID NO:13. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cd265_11 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cd265_11 should be approximately 1600 bp.

The nucleotide sequence disclosed herein for cd265_11 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cd265_11 demonstrated at least some similarity with sequences identified as AA125395 (mp77f05.r1 Soares 2NbMT Mus musculus cDNA clone 575265 5'), AA131340 (zo08h01.s1 Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone 567121 3'), AA244194 (nc06b11.s1 NCI_CGAP_Pr1 Homo sapiens cDNA clone 1462), AA339557 (EST44738 Fetal brain I Homo sapiens cDNA 5' end), AA569649 (nf24a11.s1 NCI_CGAP_Pr1 Homo sapiens cDNA clone IMAGE:914684), and T26052 (Human gene signature HUMGS08288). Based upon sequence similarity, cd265_11 proteins and each similar protein or peptide may share at least some activity.

Clone "ej265_4"

A polynucleotide of the present invention has been identified as clone "ej265_4". ej265_4 was isolated from a human adult placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ej265_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ej265_4 protein").

The nucleotide sequence of ej265_4 as presently determined is reported in SEQ ID NO:15. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ej265_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16. Amino acids 11 to 23 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ej265_4 should be approximately 1200 bp.

The nucleotide sequence disclosed herein for ej265_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ej265_4 demonstrated at least some similarity with sequences identified as D79053 (Human placenta cDNA 5'-end GEN-530B12), H63156 (yr50c03.r1

Homo sapiens cDNA clone 208708 5'), H64584 (yu14a12.r1 Homo sapiens cDNA clone 233758 5'), and T49682 (ya78f10.r1 Homo sapiens cDNA clone 67819 5'). The predicted amino acid sequence disclosed herein for ej265_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The
5 predicted ej265_4 protein demonstrated at least some similarity to sequences identified as endothelial leukocyte adhesion molecule 1. Based upon sequence similarity, ej265_4 proteins and each similar protein or peptide may share at least some activity.

Clone "ey29_8"

10 A polynucleotide of the present invention has been identified as clone "ey29_8". ey29_8 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer
15 analysis of the amino acid sequence of the encoded protein. ey29_8 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ey29_8 protein").

The nucleotide sequence of ey29_8 as presently determined is reported in SEQ ID NO:17. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ey29_8 protein corresponding to the foregoing
20 nucleotide sequence is reported in SEQ ID NO:18. Amino acids 47 to 59 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 60.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ey29_8 should be approximately 4000 bp.

25 The nucleotide sequence disclosed herein for ey29_8 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ey29_8 demonstrated at least some similarity with sequences identified as AA262521 (zs17b02.r1 Soares NbHTGBC Homo sapiens cDNA clone 685419 5'), AA429923 (zw66g01.s1 Soares testis NHT Homo sapiens cDNA clone 781200
30 3'), AA446080 (zw66g03.r1 Soares testis NHT Homo sapiens cDNA clone 781204 5'), F07905 (H. sapiens partial cDNA sequence; clone c-2lb06), U25125 (Gallus gallus preprogastrin gene, complete cds), W92743 (zd92g06.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 356986 3'), and Z44092 (H. sapiens partial cDNA sequence;

clone c-1sd04). Based upon sequence similarity, ey29_8 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the ey29_8 protein sequence, one centered around amino acid 120 and another around amino acid 410 of SEQ ID NO:18.

5

Clone "gm114_10"

A polynucleotide of the present invention has been identified as clone "gm114_10". gm114_10 was isolated from a human adult uterus cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was
10 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. gm114_10 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "gm114_10 protein").

The nucleotide sequence of gm114_10 as presently determined is reported in SEQ
15 ID NO:19. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the gm114_10 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:20.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone gm114_10 should be approximately 4000 bp.

20 The nucleotide sequence disclosed herein for gm114_10 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. gm114_10 demonstrated at least some similarity with sequences identified as AC002350 (Homo sapiens; HTGS phase 1, 46 unordered pieces), H96041 (yw61b08.r1 Soares placenta 8to9weeks 2NbHP8to9W Homo sapiens cDNA clone 256695
25 5'), L02529 (Rattus norvegicus Drosophila polarity gene (frizzled) homologue mRNA, complete cds), N70776 (za72g04.s1 Homo sapiens cDNA clone 298134 3'), N96041, N92163 (yz89b04.r1 Homo sapiens cDNA clone 290191 5'), U20865 (Saccharomyces cerevisiae chromosome XII cosmid 9672), and W93041 (zd93e07.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 357060 3'. The predicted amino acid sequence
30 disclosed herein for gm114_10 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted gm114_10 protein demonstrated at least some similarity to sequences identified as U20865 (chromosome XII cosmid 9672 [Saccharomyces cerevisiae], similar to C. elegans hypothetical protein

C34E10.2 (GenBank accession number U10402)). Based upon sequence similarity, gm114_10 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the gm114_10 protein sequence centered around amino acid 150 of SEQ ID NO:20.

Deposit of Clones

Clones as294_3, aw92_1, bd316_2, bk130_4, bv131_5, bv227_1, cd265_11, ej265_4, ey29_8, and gm114_10 were deposited on June 3, 1997 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98444, from which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

Each clone has been transfected into separate bacterial cells (*E. coli*) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an

oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

	<u>Clone</u>	<u>Probe Sequence</u>
5	as294_3	SEQ ID NO:21
	aw92_1	SEQ ID NO:22
	bd316_2	SEQ ID NO:23
	bk130_4	SEQ ID NO:24
	bv131_5	SEQ ID NO:25
10	bv227_1	SEQ ID NO:26
	cd265_11	SEQ ID NO:27
	ej265_4	SEQ ID NO:28
	ey29_8	SEQ ID NO:29
	gm114_10	SEQ ID NO:30

15

In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoramidite residue rather than a nucleotide (such as , for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

20

The design of the oligonucleotide probe should preferably follow these parameters:

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
- 25 (b) It should be designed to have a T_m of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with γ - ^{32}P ATP (specific activity 6000 Ci/mmol) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated
 30 label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately $4\text{e}+6$ dpm/pmol.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 μ g/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in
5 fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 μ g/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

10 Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 μ g/ml of yeast RNA, and 10 mM EDTA (approximately
15 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to $1e+6$ dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes.
20 A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

25 The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example,
30 as described in H.U. Saragovi, *et al.*, Bio/Technology 10, 773-778 (1992) and in R.S. McDowell, *et al.*, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to

the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

5 The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or
10 other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form.

 The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are
15 derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed
20 herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

25 Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, *Trends Pharmacol. Sci.* 15(7): 250-254; Lavarosky *et al.*, 1997,
30 *Biochem. Mol. Med.* 62(1): 11-22; and Hampel, 1998, *Prog. Nucleic Acid Res. Mol. Biol.* 58: 1-39; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided.

Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the
5 polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, *Bioessays* 14(9): 629-633; Zwaal *et al.*, 1993, *Proc. Natl.*
10 *Acad. Sci. USA* 90(16): 7431-7435; Clark *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour *et al.*, 1988, *Nature* 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These
15 organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

20 Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with
25 known techniques for determination of such domains from sequence information.

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95%
30 identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that

shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*, *Cricetulus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuánez, 1988, *Ann. Rev. Genet.* 22: 323-351; O'Brien *et al.*, 1993, *Nature Genetics* 3:103-112; Johansson *et al.*, 1995, *Genomics* 25: 682-690; Lyons *et al.*, 1997, *Nature Genetics* 15: 47-56; O'Brien *et al.*, 1997, *Trends in Genetics* 13(10): 393-399; Carver and Stubbs, 1997, *Genome Research* 7:1123-1137; all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90%

identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and
5 screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly
10 stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) [‡]	Hybridization Temperature and Buffer [†]	Wash Temperature and Buffer [†]
A	DNA:DNA	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
B	DNA:DNA	<50	T _B *; 1xSSC	T _B *; 1xSSC
C	DNA:RNA	≥ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
D	DNA:RNA	<50	T _D *; 1xSSC	T _D *; 1xSSC
E	RNA:RNA	≥ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
F	RNA:RNA	<50	T _F *; 1xSSC	T _F *; 1xSSC
G	DNA:DNA	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
H	DNA:DNA	<50	T _H *; 4xSSC	T _H *; 4xSSC
I	DNA:RNA	≥ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
J	DNA:RNA	<50	T _J *; 4xSSC	T _J *; 4xSSC
K	RNA:RNA	≥ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide	67°C; 1xSSC
L	RNA:RNA	<50	T _L *; 2xSSC	T _L *; 2xSSC
M	DNA:DNA	≥ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide	50°C; 2xSSC
N	DNA:DNA	<50	T _N *; 6xSSC	T _N *; 6xSSC
O	DNA:RNA	≥ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
P	DNA:RNA	<50	T _P *; 6xSSC	T _P *; 6xSSC
Q	RNA:RNA	≥ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
R	RNA:RNA	<50	T _R *; 4xSSC	T _R *; 4xSSC

[‡]: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

[†]: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

*T_B - T_R: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81.5 + 16.6(log₁₀[Na⁺]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1xSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial

strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant

methyI or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance
5 with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

10 The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith,
15 including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally
20 provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another
25 amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be
30 expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

Research Uses and Utilities

10 The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris *et al.*, 1993, *Cell* 75: 791-803 and in Rossi *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

30 The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine

levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially
5 binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

10 Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook,
15 J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as
20 nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or
25 capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either
30 inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is

evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

- 5 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-
10 Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bertagnolli et al., *J. Immunol.* 145:1706-1712, 1990; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Bertagnolli, et al., *J. Immunol.* 149:3778-3783, 1992; Bowman et al., *J. Immunol.* 152: 1756-1761, 1994.

- 15 Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and
20 Measurement of mouse and human Interferon γ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

- Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons,
25 Toronto. 1991; deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature* 336:690-692, 1988; Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991;
30 Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991;
Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for

example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an
5 immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves
10 inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

15 Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue
20 transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a
25 monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an
30 immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or

tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/*lpr/lpr* mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of

viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.

Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

10 The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnoli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

25 Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

30 Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter

7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent

myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland,

H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

Tissue Growth Activity

5 A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

10 A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De*
15 *novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce
20 differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

25 Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and
30 other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. *De novo* tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of

congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

- 5 A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

- 10 Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

- 15 Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

Activin/Inhibin Activity

- 20 A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, 30 United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

5

Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells.

10 Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses

15 against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population

20 of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent

25 chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene

30 Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and

Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 5 1995.

Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in 10 the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat 15 inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting 20 from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major 25 roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

30 The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the

first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

5 E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to
10 their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention
15 encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue
20 in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and
25 polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the
30 cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used

to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

10 Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

20 Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic

lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING

10 A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term
15 "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11,
20 IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included
25 in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

30 A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be

administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred

pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The
5 pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone.
10 Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not
15 increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μ g to about 100 mg (preferably about 0.1mg to about 10 mg, more preferably about 0.1 μ g to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the
20 present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous
25 therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the
30 carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal

antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting
5 and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When
10 administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also
15 optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the
20 developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular
25 application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins
30 or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-

aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns.

5 In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-
10 methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20
15 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

20 In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

25 The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering
30 various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in

the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

5 Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without
10 limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

15 Patent and literature references cited herein are incorporated by reference as if fully set forth.

SEQUENCE LISTING

5 (1) GENERAL INFORMATION:

10 (i) APPLICANT: Jacobs, Kenneth
McCoy, John M.
LaVallie, Edward R.
Racie, Lisa A.
Treacy, Maurice
Spaulding, Vikki
Agostino, Michael J.
Howes, Steven H.
15 Fechtel, Kim

(ii) TITLE OF INVENTION: SECRETED PROTEINS AND POLYNUCLEOTIDES
ENCODING THEM

20 (iii) NUMBER OF SEQUENCES: 32

(iv) CORRESPONDENCE ADDRESS:

25 (A) ADDRESSEE: Genetics Institute, Inc.
(B) STREET: 87 CambridgePark Drive
(C) CITY: Cambridge
(D) STATE: MA
(E) COUNTRY: U.S.A.
(F) ZIP: 02140

30 (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

35 (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

40 (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Sprunger, Suzanne A.
(B) REGISTRATION NUMBER: 41,323

45 (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 498-8284
(B) TELEFAX: (617) 876-5851

50 (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

55 (A) LENGTH: 1755 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAGTGGAGTC TGTACTGGCT GCGGGGGACC CTGCTCATTT GAAAATCTGA CATCAGCTGG 60
GCAGTCGCCC CCCTCCTCCT TTCCTCCCTC TACTCTGACA CAGCACTTAG CACCTGAATC 120
TTCGTTTCTC TCCCAGGGAC CCTCCATTTT CCATATCCAG GAAAATGTGA TGCGCCACAG 180
GTATCAGCGT CTGGATCGCC ACTTCACGTT TTAGCCACAA GTGACTCACT GGAAGATCCA 240
GAGTCAACAG AGGCTCGTCA GGAAGATGTC TACAGAAAAG GTAGACCAA AGGAGGAAGC 300
TGGGGAAAAA GAGGTGTGCG GAGACCAGAT CAARGGACCG GACAAAGAGG AGGAACCACC 360
AGCTCCTGCA TCCCATGGCC AGGGGTGGCG TCCAGGTGGC AGAGCAGCTA GGAACGCAAG 420
GCCTGAACCT GGGGCCAGAC ACCCTGCTCT CCCGCCATG GTCAACGACC CTCCAGTACC 480
TGCCTTACTG TGGGCCCAGG AGGTGGGCCA AGTCTTGCA GGCCGTGCCC GCAGGCTGCT 540
GCTGCAGTTT GGGGTGCTCT TCTGCACCAT CCTCCTTTTG CTCTGGGTGT CTGTCTTCCT 600
CTATGGCTCC TTCTACTATT CCTATATGCC GACAGTCAGC CACCTCAGCC CTGTGCATTT 660
CTACTACAGG ACCGACTGTG ATTCCTCCAC CACCTCACTC TGCTCCTTCC CTGTTGCCAA 720
TGTCTCGCTG ACTAAGGGTG GACGTGATCG GGTGCTGATG TATGGACAGC CGTATCGTGT 780
TACCTTAGAG CTTGAGCTGC CAGAGTCCCC TGTGAATCAA GATTGTTGGCA TGTTCTTGGT 840
CACCATTTC TGTACACCA GAGGTGGCCG AATCATCTCC ACTTCTTCGC GTTCGGTGTAT 900
GCTGCATTAC CGCTCAGACC TGCTCCAGAT GCTGGACACA CTGGTCTTCT CTAGCCTCCT 960
GCTATTTGGC TTGTCAGAGC AGAAGCAGCT GCTGGAGGTG GAACTCTACG CAGACTATAG 1020
AGAGAACTCG TACGTCCGA CCACTGGAGC GATCATTGAG ATCCACAGCA AGCGCATCCA 1080
GCTGTATGGA GCCTACCTCC GCATCCACGC GCACTTCACT GGGCTCAGAT ACCTGCTATA 1140
CAACTTCCCG ATGACCTGCG CCTTCATAGG TGTTGCCAGC AACTTCACCT TCCTCAGCGT 1200
CATCGTGCTC TTCAGCTACA TGCAGTGGGT GTGGGGGGGC ATCTGGCCCC GACACCGCTT 1260
CTCTTTGCAG GTTAACATCC GAAAAGAGA CAATTCCCGG AAGGAAGTCC AACGAAGGAT 1320
CTCTGCTCAT CAGCCAGGGC CTGAAGGCCA GGAGGAGTCA ACTCCGCAAT CAGATGTTAC 1380
AGAGGATGGT GAGAGCCCTG AAGATCCCTC AGGGACAGAG GGTCAGCTGT CCGAGGAGGA 1440

GAAACCAGAT CAGCAGCCCC TGAGCGGAGA AGAGGAGCTA GAGCCTGAGG CCACTGATGG 1500
 TTCAGGCTCC TGGGAAGATG CAGCTTTGCT GACGGAGGCC AACCTGCCTG CTCCTGCTCC 1560
 5 TGCTTCTGCT TCTGCCCTG TCCTAGAGAC TCTGGGCAGC TCTGAACCTG CTGGGGGTGC 1620
 TCTCCGACAG CGCCCCACCT GCTCTAGTTC CTGAAGAAAA GGGGCAGACT CCTCACATTC 1680
 10 CAGCACTTTC CCACCTGACT CCTCTCCCCT CGTTTTTCCT TCAATAAACT ATTTTGTGTC 1740
 AAAAAAAAAA AAAAA 1755

(2) INFORMATION FOR SEQ ID NO:2:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 462 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ser Thr Glu Lys Val Asp Gln Lys Glu Glu Ala Gly Glu Lys Glu
 1 5 10 15
 Val Cys Gly Asp Gln Ile Lys Gly Pro Asp Lys Glu Glu Glu Pro Pro
 20 25 30
 Ala Ala Ala Ser His Gly Gln Gly Trp Arg Pro Gly Gly Arg Ala Ala
 35 40 45
 Arg Asn Ala Arg Pro Glu Pro Gly Ala Arg His Pro Ala Leu Pro Ala
 50 55 60
 40 Met Val Asn Asp Pro Pro Val Pro Ala Leu Leu Trp Ala Gln Glu Val
 65 70 75 80
 Gly Gln Val Leu Ala Gly Arg Ala Arg Arg Leu Leu Leu Gln Phe Gly
 85 90 95
 45 Val Leu Phe Cys Thr Ile Leu Leu Leu Leu Trp Val Ser Val Phe Leu
 100 105 110
 Tyr Gly Ser Phe Tyr Tyr Ser Tyr Met Pro Thr Val Ser His Leu Ser
 115 120 125
 50 Pro Val His Phe Tyr Tyr Arg Thr Asp Cys Asp Ser Ser Thr Thr Ser
 130 135 140
 55 Leu Cys Ser Phe Pro Val Ala Asn Val Ser Leu Thr Lys Gly Gly Arg

	145	150	155	160
	Asp Arg Val Leu Met Tyr Gly Gln Pro Tyr Arg Val Thr Leu Glu Leu			175
		165	170	
5	Glu Leu Pro Glu Ser Pro Val Asn Gln Asp Leu Gly Met Phe Leu Val			190
		180	185	
	Thr Ile Ser Cys Tyr Thr Arg Gly Gly Arg Ile Ile Ser Thr Ser Ser			205
10		195	200	
	Arg Ser Val Met Leu His Tyr Arg Ser Asp Leu Leu Gln Met Leu Asp			220
		210	215	
15	Thr Leu Val Phe Ser Ser Leu Leu Leu Phe Gly Phe Ala Glu Gln Lys			240
		225	230	235
	Gln Leu Leu Glu Val Glu Leu Tyr Ala Asp Tyr Arg Glu Asn Ser Tyr			255
		245	250	
20	Val Pro Thr Thr Gly Ala Ile Ile Glu Ile His Ser Lys Arg Ile Gln			270
		260	265	
	Leu Tyr Gly Ala Tyr Leu Arg Ile His Ala His Phe Thr Gly Leu Arg			285
25		275	280	
	Tyr Leu Leu Tyr Asn Phe Pro Met Thr Cys Ala Phe Ile Gly Val Ala			300
		290	295	
30	Ser Asn Phe Thr Phe Leu Ser Val Ile Val Leu Phe Ser Tyr Met Gln			320
		305	310	315
	Trp Val Trp Gly Gly Ile Trp Pro Arg His Arg Phe Ser Leu Gln Val			335
		325	330	
35	Asn Ile Arg Lys Arg Asp Asn Ser Arg Lys Glu Val Gln Arg Arg Ile			350
		340	345	
	Ser Ala His Gln Pro Gly Pro Glu Gly Gln Glu Glu Ser Thr Pro Gln			365
40		355	360	
	Ser Asp Val Thr Glu Asp Gly Glu Ser Pro Glu Asp Pro Ser Gly Thr			380
		370	375	
45	Glu Gly Gln Leu Ser Glu Glu Glu Lys Pro Asp Gln Gln Pro Leu Ser			400
		385	390	395
	Gly Glu Glu Glu Leu Glu Pro Glu Ala Ser Asp Gly Ser Gly Ser Trp			415
		405	410	
50	Glu Asp Ala Ala Leu Leu Thr Glu Ala Asn Leu Pro Ala Pro Ala Pro			430
		420	425	
	Ala Ser Ala Ser Ala Pro Val Leu Glu Thr Leu Gly Ser Ser Glu Pro			445
55		435	440	

Ala Gly Gly Ala Leu Arg Gln Arg Pro Thr Cys Ser Ser Ser
450 455 460

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3213 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGAATAGAGG ATTTCAAAAA GCATGCGTTT TTTGAAGGTC TAAATTGGGA AAATATACGA 60
AACCTAGAAG CACCTTATAT TCCTGATGTG AGCAGTCCCT CTGACACATC CAACTTCGAC 120
GTGGATGACG ACGTGCTGAG AACACGGAA ATATTACCTC CTGGTTCTCA CACAGGCTTT 180
TCTGGATTAC ATTTGCCATT CATTGGTTTT ACATTCACAA CGGAAAGCTG TTTTCTGAT 240
CGAGGCTCTC TGAAGAGCAT AATGCAGTCC AACACATTAA CCAAAGATGA GGATGTGCAG 300
CGGGACCTGG AGCACAGCCT GCAGATGGAA GCTTACGAGA GGAGGATTCG GAGGCTGGAA 360
CAGGAGAAGC TGGAGCTGAG CAGGAAGCTG CAAGAGTCCA CCCAGACCGT GCAGTCCCTC 420
CACGGCTCAT CTCGGGCCCT CAGCAATTCA AACCGAGATA AAGAAATCAA AAAGCTAAAT 480
GAAGAAATCG AACGCTTGAA GAATAAAATA GCAGATTCAA ACAGGCTGGA GCGACAGCTT 540
GAGGACACAG TGGCGCTTCG CCAAGAGCGT GAGGACTCCA CGCAGCGGCT GCGGGGGCTG 600
GAGAAGCAGC ACCGCGTGGT CCGGCAGGAG AAGGAGGAGC TGCACAAGCA ACTGGTTGAA 660
GCCTCAGAGC GGTGAAATC CCAGGCCAAG GAACTCAAAG ATGCCCATCA GCAGCGAAAG 720
CTGGCCCTGC AGGAGTTCTC GGAGCTGAAC GAGCGCATGG CAGAGCTCCG TGCCCAGAAG 780
CAGAAGGTGT CCCGGCAGCT GCGAGACAAG GAGGAGGAGA TGGAGGTGGC CACGCAGAAG 840
GTGGACGCCA TGCGGCAGGA AATGCGGAGA GCTGAGAAGC TCAGGAAAGA GCTGGAAGCT 900
CAGCTTGATG ATGCTCTTGC TGAGGCCTCC AAGGAGCGCA AGCTTCGTGA GCACAGCGAG 960
AACTTCTGCA AGCAAATGGA AAGCGAGCTG GAGGCCCTCA AGGTGAAGCA AGGAGGCCGG 1020
GGAGCGGGTG CCACCTTAGA GCACCAGCAA GAGATTTCCA AAATCAAATC CGAGCTGGAG 1080
AAGAAAGTCT TATTTTATGA AGAGGAATTG GTCAGACGTG AGGCCTCCCA TGTGCTAGAA 1140

GTGAAAAATG TGAAGAAGGA GGTGCATGAT TCAGAAAGCC ACCAGCTGGC CCTGCAGAAA 1200
GAAATCTTGA TGTTAAAAGA TAAGTTAGAA AAGTCAAAGC GAGAACGGCA TAACGAGATG 1260
5 GAGGAGGCAG TAGGTACAAT AAAAGATAAA TACGAACGAG AAAGAGCGAT GCTGTTTGAT 1320
GAAAACAAGA AGCTAACTGC TGAAAATGAA AAGCTCTGTT CCTTTGTGGA TAAACTCACA 1380
GCTCAAAATA GACAGCTGGA GGATGAGCTG CAGGATCTGG CAGCCAAGAA GGAGTCAGTG 1440
10 GCCCACTGGG AAGCTCAGAT TGC GGAAATC ATTCACTGGG TCAGTGACGA GAAAGATGCC 1500
CGGGGTTACC TTCAAGCTCT TGCTTCCAAG ATGACCGAAG AGCTCGAGGC TTTGAGGAGT 1560
15 TCTAGTCTGG GGTCAAGAAC ACTGGACCCG CTGTGGAAGG TGCGCCGAG CCAGAAGCTG 1620
GACATGTCCG CGCGGCTGGA GCTGCAGTCG GCCCTGGAGG CGGAGATCCG GGCCAAGCAG 1680
CTTGTCCAGG AGGAGCTCAG GAAGGTCAAG GACGCCAACC TCACCTTGGA AAGCAAACYA 1740
20 AWGGATTCCG AAGCCAAAAA CAGAGAATTA TTAGAAGAAA TGGAAATTTT GAAGAAAAAG 1800
ATGGAAGAAA AATTCAGAGC AGATACTGGG CTCAAACCTC CAGATTTTCA GGATTCCATT 1860
25 TTTGAGTATT TCAACACTGC TCCTCTTGCA CATGACCTGA CATTTAGAAC CAGCTCAGCT 1920
AGTGAGCAAG AAACACAAGC TCCGAAGCCA GAAGCGTCCC CGTCGATGTC TGTGGCTGCA 1980
TCAGAGCAGC AGGAGGACAT GGCTCGGCCC CCGCAGAGGC CATCCGCTGT GCCGTTGCCC 2040
30 ACCACGCAGG CCCTGGCTCT GGCTGGACCG AAGCCAAAAG CTCACCAGTT CAGCATCAAG 2100
TCCTTCTCCA GCCCTACTCA GTGCAGCCAC TGCACCTCCC TGATGGTTGG GCTGATCCGG 2160
35 CAGGGCTACG CCTGCGAGGT GTGTTCTTTT GCTTGCCACG TGTCTGCAA AGACGGTGCC 2220
CCCCAGGTGT GCCCAATACC TCCCGAGCAG TCCAAGAGGC CTCTGGGCGT GGACGTGCAG 2280
CGAGGCATCG GAACAGCCTA CAAAGGCCAT GTCAAGGTCC CAAAGCCCAC GGGGGTGAAG 2340
40 AAGGGATGGC AGCGCGCATA TGCACTCGTC TGTGACTGCA AGCTCTTCCT GTATGATCTG 2400
CCTGAAGGAA AATCCACCCA GCCTGGTGTC ATTGCGAGCC AAGTCTTGGA TCTCAGAGAT 2460
45 GACGAGTTTT CCGTGAGCTC AGTCCTGGCC TCAGATGTCA TTCATGCTAC ACGCCGAGAT 2520
ATTCCATGTA TATTCAGGGT GACGGCCTCT CTCTTAGGTG CACCTTCTAA GACCAGCTCG 2580
CTGCTCATTC TGACAGAAAA TGAGAATGAA AAGAGGAAGT GGGTTGGGAT TCTAGAAGGA 2640
50 CTCCAGTCCA TCCTTCATAA AAACCGGCTG AGGAATCAGG TCGTGATGT TCCCTTGGA 2700
GCCTACGACA GCTCGCTGCC TCTCATCAAG GCCATCCTGA CAGCTGCCAT CGTGGATGCA 2760
55 GACAGGATTG CAGTCGGCCT AGAAGAAGGG CTCTATGTCA TAGAGGTCAC CCGAGATGTG 2820

ATCGTCCGTG CCGCTGACTG TAAGAAGGTA CACCAGATCG AGCTTGCTCC CAGGGAGAAG 2880
 ATCGTAATCC TCCTCTGTGG CCGGAACCAC CATGTGCACC TCTATCCGTG GTCGTCCCTT 2940
 5 GATGGAGCGG AAGGCAGCTT TGACATCAAG CTTCCGGAAA CCAAAGGCTG CCAGCTCATG 3000
 GCCACGGCCA CACTCAAGAG GARCTCTGGC ACCTGCCTGT TTGTGGCCGT GAAACGGCTG 3060
 ATCCTTTGCT ATGAGATCCA GAAAATAAAG CCATATTGAA TGATAAAAAA AAAAAAAAAA 3120
 10 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3180
 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAA : 3213
 15 (2) INFORMATION FOR SEQ ID NO:4:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 945 amino acids
 (B) TYPE: amino acid
 20 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear.
 (ii) MOLECULE TYPE: protein
 25
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
 30 Met Gln Ser Asn Thr Leu Thr Lys Asp Glu Asp Val Gln Arg Asp Leu
 1 5 10 15
 Glu His Ser Leu Gln Met Glu Ala Tyr Glu Arg Arg Ile Arg Arg Leu
 20 25 30
 35 Glu Gln Glu Lys Leu Glu Leu Ser Arg Lys Leu Gln Glu Ser Thr Gln
 35 40 45
 Thr Val Gln Ser Leu His Gly Ser Ser Arg Ala Leu Ser Asn Ser Asn
 40 50 55 60
 Arg Asp Lys Glu Ile Lys Lys Leu Asn Glu Glu Ile Glu Arg Leu Lys
 65 70 75 80
 45 Asn Lys Ile Ala Asp Ser Asn Arg Leu Glu Arg Gln Leu Glu Asp Thr
 85 90 95
 Val Ala Leu Arg Gln Glu Arg Glu Asp Ser Thr Gln Arg Leu Arg Gly
 100 105 110
 50 Leu Glu Lys Gln His Arg Val Val Arg Gln Glu Lys Glu Glu Leu His
 115 120 125
 Lys Gln Leu Val Glu Ala Ser Glu Arg Leu Lys Ser Gln Ala Lys Glu
 130 135 140

Leu Lys Asp Ala His Gln Gln Arg Lys Leu Ala Leu Gln Glu Phe Ser
 145 150 155 160
 5 Glu Leu Asn Glu Arg Met Ala Glu Leu Arg Ala Gln Lys Gln Lys Val
 165 170 175
 Ser Arg Gln Leu Arg Asp Lys Glu Glu Glu Met Glu Val Ala Thr Gln
 180 185 190
 10 Lys Val Asp Ala Met Arg Gln Glu Met Arg Arg Ala Glu Lys Leu Arg
 195 200 205
 Lys Glu Leu Glu Ala Gln Leu Asp Asp Ala Val Ala Glu Ala Ser Lys
 210 215 220
 15 Glu Arg Lys Leu Arg Glu His Ser Glu Asn Phe Cys Lys Gln Met Glu
 225 230 235 240
 Ser Glu Leu Glu Ala Leu Lys Val Lys Gln Gly Gly Arg Gly Ala Gly
 245 250 255
 20 Ala Thr Leu Glu His Gln Gln Glu Ile Ser Lys Ile Lys Ser Glu Leu
 260 265 270
 25 Glu Lys Lys Val Leu Phe Tyr Glu Glu Glu Leu Val Arg Arg Glu Ala
 275 280 285
 Ser His Val Leu Glu Val Lys Asn Val Lys Lys Glu Val His Asp Ser
 290 295 300
 30 Glu Ser His Gln Leu Ala Leu Gln Lys Glu Ile Leu Met Leu Lys Asp
 305 310 315 320
 Lys Leu Glu Lys Ser Lys Arg Glu Arg His Asn Glu Met Glu Glu Ala
 325 330 335
 35 Val Gly Thr Ile Lys Asp Lys Tyr Glu Arg Glu Arg Ala Met Leu Phe
 340 345 350
 40 Asp Glu Asn Lys Lys Leu Thr Ala Glu Asn Glu Lys Leu Cys Ser Phe
 355 360 365
 Val Asp Lys Leu Thr Ala Gln Asn Arg Gln Leu Glu Asp Glu Leu Gln
 370 375 380
 45 Asp Leu Ala Ala Lys Lys Glu Ser Val Ala His Trp Glu Ala Gln Ile
 385 390 395 400
 Ala Glu Ile Ile Gln Trp Val Ser Asp Glu Lys Asp Ala Arg Gly Tyr
 405 410 415
 50 Leu Gln Ala Leu Ala Ser Lys Met Thr Glu Glu Leu Glu Ala Leu Arg
 420 425 430
 55 Ser Ser Ser Leu Gly Ser Arg Thr Leu Asp Pro Leu Trp Lys Val Arg

78

Ser Val Ser Ser Val Leu Ala Ser Asp Val Ile His Ala Thr Arg Arg
 740 745 750
 5 Asp Ile Pro Cys Ile Phe Arg Val Thr Ala Ser Leu Leu Gly Ala Pro
 755 760 765
 Ser Lys Thr Ser Ser Leu Leu Ile Leu Thr Glu Asn Glu Asn Glu Lys
 770 775 780
 10 Arg Lys Trp Val Gly Ile Leu Glu Gly Leu Gln Ser Ile Leu His Lys
 785 790 795 800
 Asn Arg Leu Arg Asn Gln Val Val His Val Pro Leu Glu Ala Tyr Asp
 805 810 815
 15 Ser Ser Leu Pro Leu Ile Lys Ala Ile Leu Thr Ala Ala Ile Val Asp
 820 825 830
 Ala Asp Arg Ile Ala Val Gly Leu Glu Glu Gly Leu Tyr Val Ile Glu
 835 840 845
 20 Val Thr Arg Asp Val Ile Val Arg Ala Ala Asp Cys Lys Lys Val His
 850 855 860
 Gln Ile Glu Leu Ala Pro Arg Glu Lys Ile Val Ile Leu Leu Cys Gly
 865 870 875 880
 25 Arg Asn His His Val His Leu Tyr Pro Trp Ser Ser Leu Asp Gly Ala
 885 890 895
 30 Glu Gly Ser Phe Asp Ile Lys Leu Pro Glu Thr Lys Gly Cys Gln Leu
 900 905 910
 Met Ala Thr Ala Thr Leu Lys Arg Xaa Ser Gly Thr Cys Leu Phe Val
 915 920 925
 35 Ala Val Lys Arg Leu Ile Leu Cys Tyr Glu Ile Gln Lys Ile Lys Pro
 930 935 940
 40 Tyr
 945

(2) INFORMATION FOR SEQ ID NO:5:

- 45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1315 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear
 50 (ii) MOLECULE TYPE: cDNA

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

	GAGGGCACTT AATCCCAATG AACTGTATGC TTAAAAATAA TTAAATGAT AAACTTTGTG	60
5	TTATGTATAC TTACCACAA TAAGAAAAAG TATTTTAGTA CTAGTGGTAA ATAGTTTTTA	120
	TTTAATAGAC TTATATTTTA AAGCTTAAAA ATAATTTAGC TTCTAGAGTA TTACGTTTTT	180
10	CTTCATGGGA ACTTCAAAAA GCAAGTCACT AAATCCAAGA ATTTTAAAGA AAAAACCCAA	240
	ATACATGATT TATGCTGCAT CTGGTATAGA TTTTAAAG ACTAGTCAAT CTAAGCTCTA	300
	AACTATTAAA TGACAAACCA TTTCATATGT CATTGCATAT TCCTATGTAC CACATTCTCA	360
15	TATTTCTGTT ATGGGCATGA AGGGGTGTTT GATGCTTCCA TGCCATAATA ACCATGACTA	420
	TCACAACCAT TGAAATAAAG GTTCTGTCAG TATTTTCAGG ATGGTCCCAG AAATTTAAAT	480
20	TAATCTCTCA TCCATTGGCT TTTGCTACTT TAGGTTAATA TAAAAATATA ACATACATTT	540
	TTGGGGTTTA TGCTGTTAGC TCCAAACCAA AAGATTTTGG AAATTTATTT TGGAAATTTT	600
	GTGTTTAGAA TATGAATAAA TCTGCTTATT CAGAAAAATT AAACCTTGAT AACTTGGGAC	660
25	CTCCTATTCC TGTATGTTCT CTGACATACA TTGAGGGATT TGGCTCTCTT TTGTTTATTT	720
	GTTTTACTAG TCAGACATTC CTTTGGCTGC CCATACTTAA TTCTGTTGGG TGTTCGCC	780
30	CCCGCCCTCA GCTTCTGCAG CTACTCTGAT CAACATCCGC AATGCCAGGA AACACTTTGA	840
	AAAGCTGGAA AGAGTGGATG GACCAAAGCA GTGTCTTCTC ATGCGCTAAA CATTGATGAA	900
	TATTGTTTCA CACAAAAATT AAAAGTTTCC TAATTAATGT TGTATTCATA TATGTAGGCT	960
35	CTGAAATGTT GTGATGCTTA TTGCTTCTGT ATTTCTTCTC TACTCCCTAG TCTTAATGTT	1020
	TAACCTTGAA TGCTATTAAC TTAAATAGCC ATTGAGGAGT TAGAAGATGA ATTGTTCATG	1080
40	AAGTCGGTGT TACATAAAAG TAGGTGATAT GTAAGTTTTC TGATAACAAG GTTCTAATAG	1140
	TGTTTAAATG TACTGGTAAC CTGGTTCCAA TAGTTGTGTT TGCCCAAGCC TTTCTCGGCA	1200
	TCATCTTGTA TTCCTTATCA GATAGTAAGT AACCTGTAAG TTTGGAGTAT TACTGTTTTT	1260
45	TCAGCATGCA TTAAAAATAT TCCTTAACTT CAATTGTAAA AAAAAAAAAA AAAAA	1315

(2) INFORMATION FOR SEQ ID NO:6:

- 50 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 65 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- 55 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

5 Met Asn Lys Ser Ala Tyr Ser Glu Lys Leu Asn Leu Asp Asn Leu Gly
 1 5 10 15
 10 Pro Pro Ile Pro Val Cys Ser Leu Thr Tyr Ile Glu Gly Phe Gly Ser
 20 25 30
 15 Leu Leu Phe Ile Cys Phe Thr Ser Gln Thr Phe Leu Trp Leu Pro Ile
 35 40 45
 20 Leu Asn Ser Val Gly Cys Phe Arg Pro Arg Pro Gln Leu Leu Gln Leu
 50 55 60
 25 Leu
 65

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 519 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

35 TAGGCCATGA AGGCCGAATC GGCCTTCATG GCCTACGCTT ACACAATACC CACCATGTCC 60
 CAGGCTGGTG CTCAGGAAGC CCCTATCAAG AAGAAGCGCC CCCCTGTGAA GGAGGAGGAC 120
 40 CTGAAGGGGG CCCGAGGAAA CCTGACCAAG AACCAGGAAA TCAAGTCCAA GACCTACCAG 180
 GTCATGCGAG AGTGTGAGCA AGCTGGCTCG GCCGCCCCGT CGGTGTTTCCAG CCGCACCCGC 240
 ACAGGTACCG AGACTGTCTT TGAGAAGCCC AAAGCCGGAC CCACCAAGAG TGTCTTCGGC 300
 45 TGAGAAGTGT GCGCCACTCC CCTTGCTGCC CGAATGCTCG GAAACAGGAG CCTTACCCAG 360
 GAACTCTTTT TTATGCCAGA ACGCTTCCTC TCCCCTGCTG TCTCTGGGGC TGCCACCCTC 420
 50 CCCACAGTC CAGGCCCTTC AGCCAAGGGC TCTGCACCAG CACCTTGAA GCACCAATAA 480
 AGAGGATGCC CACGTGGCCC CAGCAAAAAA AAAAAAAA 519

(2) INFORMATION FOR SEQ ID NO:8:

55

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 98 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Lys Ala Glu Ser Ala Phe Met Ala Tyr Ala Tyr Thr Ile Pro Thr
1 5 10 15
Met Ser Gln Ala Gly Ala Gln Glu Ala Pro Ile Lys Lys Lys Arg Pro
20 25 30
Pro Val Lys Glu Glu Asp Leu Lys Gly Ala Arg Gly Asn Leu Thr Lys
35 40 45
Asn Gln Glu Ile Lys Ser Lys Thr Tyr Gln Val Met Arg Glu Cys Glu
50 55 60
Gln Ala Gly Ser Ala Ala Pro Ser Val Phe Ser Arg Thr Arg Thr Gly
65 70 75 80
Thr Glu Thr Val Phe Glu Lys Pro Lys Ala Gly Pro Thr Lys Ser Val
85 90 95
Phe Gly

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2788 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GACGGCGACC AAACCCAGCT AGGTCAGACG AGAAAGATAA AACTCTCCA GATGTCTTCC 60
AGTAATGTCG AAGTTTTTAT CCCAGTGTCA CAAGGAAACA CCAATGGCTT CCCC GCGACA 120
GCTTCCAATG ACCTGAAGGC ATTTACTGAA GGAGCTGTGT TAAGTTTTC TAACATCTGC 180

TATCGAGTAA AACTGAAGAG TGGCTTTCTA CCTTGTCGAA AACCAGTTGA GAAAGAAATA 240
 TTATCGAATA TCAATGGGAT CATGAAACCT GGTCTCAACG CCATCCTGGG ACCCACAGGT 300
 5 GGARGCAAAT CTTCGTTATT AGATGTCTTA GCTGCAAGGA AAGATCCAAG TGGATTATCT 360
 GGAGATGTTT TGATAAATGG AGCACCGCGA CCTGCCAATT TCAAATGTAA TTCAGGTTAC 420
 GTGGTACAAG TTGGAAGTCA GTTTATCCGT GGTGTGTCTG GAGGAGAAAG AAAAAGGACT 480
 10 AGTATAGGAA TGGAGCTTAT CACTGATCCT TCCATCTTGT TCTTGATGA GCCTACAAC 540
 GGCTTAGACT CAAGCACAGC AAATGCTGTC CTTTGTCTCC TGAAAAGGAT GTCTAAGCAG 600
 15 GGACGAACAA TCATCTTCTC CATTATCAG CCTCGATATT CCATCTTCAA GTTGTTTGAT 660
 AGCCTCACCT TATTGGCCTC AGGAAGACTT ATGTTCCACG GGCCTGCTCA GGAGGCCTTG 720
 GGATACTTTG AATCAGCTGG TTATCACTGT GAGGCCTATA ATAACCCTGC AGACTTCTTC 780
 20 TTGGACATCA TTAATGGAGA TTCCACTGCT GTGGCATTAA ACAGAGAAGA AGACTTTAAA 840
 GCCACAGAGA TCATAGAGCC TTCCAAGCAG GATAAGCCAC TCATAGAAAA ATTAGCGGAG 900
 25 ATTTATGTCA ACTCCTCCTT CTACAAAGAG ACAAAGCTG AATTACATCA ACTTTCCGGG 960
 GGTGAGAAGA AGAAGAAGAT CACAGTCTTC AAGGAGATCA GCTACACCAC CTCCTTCTGT 1020
 CATCAACTCA GATGGGTTTC CAAGCGTTCA TTCAAAACT TGCTGGGTAA TCCCCAGGCC 1080
 30 TCTATAGCTC AGATCATTGT CACAGTCGTA CTGGGACTGG TTATAGGTGC CATTTACTTT 1140
 GGGCTAAAAA ATGATTCTAC TGGAATCCAG AACAGAGCTG GGGTTCTCTT CTTCTGACG 1200
 35 ACCAACCAGT GTTTCAGCAG TGTTTCAGCC GTGGAAGTCT TTGTGGTAGA GAAGAAGCTC 1260
 TTCATACATG AATACATCAG CGGATACTAC AGAGTGTCTT CTTATTTCTT TGGAAACTG 1320
 TTATCTGATT TATTACCCAT GAGGATGTTA CCAAGTATTA TATTTACCTG TATAGGTAC 1380
 40 TTCATGTTAG GATTGAAGCC AAAGGCAGAT GCCTTCTTCG TTATGATGTT TACCCCTATG 1440
 ATGGTGGCTT ATTCAGCCAG TTCCATGGCA CTGGCCATAG CAGCAGGTCA GAGTGTGGTT 1500
 45 TCTGTAGCAA CACTTCTCAT GACCATCTGT TTTGTGTTTA TGATGATTTT TTCAGGTCTG 1560
 TTGGTCAATC TCACAACCAT TGCATCTTGG CTGTCATGGC TTCAGTACTT CAGCATTCCA 1620
 CGATATGGAT TTACGGCTTT GCAGCATAAT GAATTTTGG GACAAACTT CTGCCAGGA 1680
 50 CTCAATGCAA CAGGAAACAA TCCTTGTAAC TATGCAACAT GTACTGGCGA AGAATATTTG 1740
 GTAAAGCAGG GCATCGATCT CTCACCCTGG GGCTTGTGGA AGAATCACGT GGCCTTGGCT 1800
 55 TGTATGATTG TTATTTTCCT CACAATTGCC TACCTGAAAT TGTTATTTCT TAAAAATAT 1860

TCTTAAATTT CCCCTTAATT CAGTATGATT TATCCTCACA TAAAAAAGAA GCACTTTGAT 1920
 TGAAGTATTC AATCAAGTTT TTTTGGTTGT TTTCTGTTCC CTGCCATCA CACTGTTGCA 1980
 5 CAGCAGCAAT TGTTTTAAAG AGATACATTT TTAGAAATCA CAACAACTG AATTAAACAT 2040
 GAAAGAACCC AAGACATCAT GTATCGCATA TTAGTTAATC TCCTCAGACA GTAACCATGG 2100
 10 GGAAGAAATC TGGTCTAATT TATTAATCTA AAAAAGGAGA ATTGAATTCT GGAAACTCCT 2160
 GACAAGTTAT TACTGTCTCT GGCATTTGTT TCCTCATCTT TAAAATGAAT AGGTAGGTTA 2220
 GTAGCCCTTC AGTCTTAATA CTTTATGATG CTATGGTTTG CCATTATTTA ATAAATGACA 2280
 15 AATGTATTAA TGCTAAAAA AAAAAAAAAA AGCGGCCTTC ATGGCCTAGA GATTTCAACT 2340
 TAACTTGACC GCTCTGAGCT AAACCTAGCC CCAAACCCAC TCCACCTTAT TACCAGACAA 2400
 CCTTAACCAA ACCATTTACC CAAATAAGT ATAGGCGATA GAAATTGAAA CCTGGCGCAA 2460
 20 TAGATATAGT ACCGCAAGGG AAAGATGAAA AATTATAACC AAGCATAATA TAGCAAGGAC 2520
 TAACCCCTAT ACCTTCTGCA TAATGAATTA ACTAGAAATA ACTTTGCAAG GAGAGCCAAA 2580
 25 GCTAAGACCC CCGAAACCAG ACGAGCTACC TAAGAACAGC TAAAAGAGCA CACCCGTCTA 2640
 TGTAGCAAAA TAGTGGAAG ATTTATAGGT AGAGGCGACA AACCTACCGA GCCTGGTGAT 2700
 AGCTGGTTGT CCCAGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 2760
 30 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA
 2788

(2) INFORMATION FOR SEQ ID NO:10:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 604 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 40 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

50 Met Ser Ser Ser Asn Val Glu Val Phe Ile Pro Val Ser Gln Gly Asn
 1 5 10 15
 Thr Asn Gly Phe Pro Ala Thr Ala Ser Asn Asp Leu Lys Ala Phe Thr
 20 25 30
 55 Glu Gly Ala Val Leu Ser Phe His Asn Ile Cys Tyr Arg Val Lys Leu
 35 40 45

Lys Ser Gly Phe Leu Pro Cys Arg Lys Pro Val Glu Lys Glu Ile Leu
 50 55 60
 5 Ser Asn Ile Asn Gly Ile Met Lys Pro Gly Leu Asn Ala Ile Leu Gly
 65 70 75 80
 Pro Thr Gly Gly Xaa Lys Ser Ser Leu Leu Asp Val Leu Ala Ala Arg
 85 90 95
 10 Lys Asp Pro Ser Gly Leu Ser Gly Asp Val Leu Ile Asn Gly Ala Pro
 100 105 110
 Arg Pro Ala Asn Phe Lys Cys Asn Ser Gly Tyr Val Val Gln Val Gly
 115 120 125
 15 Thr Gln Phe Ile Arg Gly Val Ser Gly Gly Glu Arg Lys Arg Thr Ser
 130 135 140
 Ile Gly Met Glu Leu Ile Thr Asp Pro Ser Ile Leu Phe Leu Asp Glu
 145 150 155 160
 20 Pro Thr Thr Gly Leu Asp Ser Ser Thr Ala Asn Ala Val Leu Leu Leu
 165 170 175
 25 Leu Lys Arg Met Ser Lys Gln Gly Arg Thr Ile Ile Phe Ser Ile His
 180 185 190
 Gln Pro Arg Tyr Ser Ile Phe Lys Leu Phe Asp Ser Leu Thr Leu Leu
 195 200 205
 30 Ala Ser Gly Arg Leu Met Phe His Gly Pro Ala Gln Glu Ala Leu Gly
 210 215 220
 Tyr Phe Glu Ser Ala Gly Tyr His Cys Glu Ala Tyr Asn Asn Pro Ala
 225 230 235 240
 35 Asp Phe Phe Leu Asp Ile Ile Asn Gly Asp Ser Thr Ala Val Ala Leu
 245 250 255
 40 Asn Arg Glu Glu Asp Phe Lys Ala Thr Glu Ile Ile Glu Pro Ser Lys
 260 265 270
 Gln Asp Lys Pro Leu Ile Glu Lys Leu Ala Glu Ile Tyr Val Asn Ser
 275 280 285
 45 Ser Phe Tyr Lys Glu Thr Lys Ala Glu Leu His Gln Leu Ser Gly Gly
 290 295 300
 Glu Lys Lys Lys Lys Ile Thr Val Phe Lys Glu Ile Ser Tyr Thr Thr
 305 310 315 320
 50 Ser Phe Cys His Gln Leu Arg Trp Val Ser Lys Arg Ser Phe Lys Asn
 325 330 335
 55 Leu Leu Gly Asn Pro Gln Ala Ser Ile Ala Gln Ile Ile Val Thr Val

340 345 350
 Val Leu Gly Leu Val Ile Gly Ala Ile Tyr Phe Gly Leu Lys Asn Asp
 355 360 365
 5 Ser Thr Gly Ile Gln Asn Arg Ala Gly Val Leu Phe Phe Leu Thr Thr
 370 375 380
 10 Asn Gln Cys Phe Ser Ser Val Ser Ala Val Glu Leu Phe Val Val Glu
 385 390 395 400
 Lys Lys Leu Phe Ile His Glu Tyr Ile Ser Gly Tyr Tyr Arg Val Ser
 405 410 415
 15 Ser Tyr Phe Leu Gly Lys Leu Leu Ser Asp Leu Leu Pro Met Arg Met
 420 425 430
 Leu Pro Ser Ile Ile Phe Thr Cys Ile Val Tyr Phe Met Leu Gly Leu
 435 440 445
 20 Lys Pro Lys Ala Asp Ala Phe Phe Val Met Met Phe Thr Leu Met Met
 450 455 460
 Val Ala Tyr Ser Ala Ser Ser Met Ala Leu Ala Ile Ala Ala Gly Gln
 465 470 475 480
 Ser Val Val Ser Val Ala Thr Leu Leu Met Thr Ile Cys Phe Val Phe
 485 490 495
 30 Met Met Ile Phe Ser Gly Leu Leu Val Asn Leu Thr Thr Ile Ala Ser
 500 505 510
 Trp Leu Ser Trp Leu Gln Tyr Phe Ser Ile Pro Arg Tyr Gly Phe Thr
 515 520 525
 35 Ala Leu Gln His Asn Glu Phe Leu Gly Gln Asn Phe Cys Pro Gly Leu
 530 535 540
 Asn Ala Thr Gly Asn Asn Pro Cys Asn Tyr Ala Thr Cys Thr Gly Glu
 545 550 555 560
 Glu Tyr Leu Val Lys Gln Gly Ile Asp Leu Ser Pro Trp Gly Leu Trp
 565 570 575
 40 Lys Asn His Val Ala Leu Ala Cys Met Ile Val Ile Phe Leu Thr Ile
 580 585 590
 Ala Tyr Leu Lys Leu Leu Phe Leu Lys Lys Tyr Ser
 595 600
 50

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2930 base pairs
 (B) TYPE: nucleic acid

55.

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

10 CGACTTCCTC GGCTGCGCGG CGCTCGCGCG GAGCTCCCCG GCCGGCGGTG CGTCCCCACG 60
GTCACCATGA AAGACGACTT CGCAGAGGAG GAGGAGGTGC AATCCTTCGG TTACAAGCGG 120
15 TTTGGTATTC AGGAAGGAAC ACAATGTACC AAATGTAAAA ATAAGTGGG ACTGAAGTTT 180
TCTATCATAT TATTATACAT TTTGTGTGCC TTGCTAACAA TCACAGTAGC CATTTTGGGA 240
TATAAAGTTG TAGAGAAAAT GGACAATGTC ACAGGTGGCA TGGAAACATC TCGCCAAACC 300
20 TATGATGACA AGCTCACAGC AGTGGAAGT GACCTGAAAA AATTAGGTGA CCAAAGTGGG 360
AAGAAAGCTA TCAGCACCAA CTCAGAACTC TCCACCTTCA GATCAGACAT TCTAGATCTC 420
25 CGTCAGCAAC TTCGTGAGAT TACAGAAAA ACCAGCAAGA ACAAGGATAC GCTGGAGAAG 480
TTACAGGCGA GCGGGGATGC TCTGGTGGAC AGGCAGAGTC AATTGAAAGA AACTTTGGAG 540
AATAACTCTT TCCTCATCAC CACTGTAAAC AAAACCTCC AGGCGTATAA TGGCTATGTC 600
30 ACGAATCTGC AGCAAGATAC CAGCGTGCTC CAGGGCAATC TGCAGAACCA AATGTATTCT 660
CATAATGTGG TCATCATGAA CTCAACAACC TGAACCTGAC CCAGGTGCAG CAGAGGAACC 720
35 TCATCACGAA TCTGCAGCGG TCTGTGGATG ACACAAGCCA GGCTATCCAG CGAATCAAGA 780
ACGACTTTCA AAATCTGCAG CAGGTTTTTC TTCAAGCCAA GAAGGACACG GATTGGCTGA 840
AGGAGAAAGT GCAGAGCTTG CAGACGCTGG CTGCCAACAA CTCTGCGTTG GCCAAAGCCA 900
40 ACAACGACAC CCTGGAGGAT ATGAACAGCC AGCTCAACTC ATTCACAGGT CAGATGGAGA 960
ACATCACCAC TATCTCTCAA GCCAACGAGC AGAACCTGAA AGACCTGCAG GACTTACACA 1020
45 AAGATGCAGA GAATAGAACA GCCATCAAGT TCAACCAACT GGAGGAACGC TTCCAGCTCT 1080
TTGAGACGGA TATTGTGAAC ATCATTAGCA ATATCAGTTA CACAGCCCAC CACCTGCGGA 1140
CGCTGACCAG CAATCTAAAT GAAGTCAGGA CCACTTGACAG AGATACCTT ACCAAACACA 1200
50 CAGATGATCT GACCTCCTTG AATAATACCC TGGCCAACAT CCGTTTGGAT TCTGTTTCTC 1260
TCAGGATGCA ACAAGATTTG ATGAGGTCGA GGTTAGACAC TGAAGTAGCC AACTTATCAG 1320
55 TGATTATGGA AGAAATGAAG CTAGTAGACT CCAAGCATGG TCAGCTCATC AAGAATTTTA 1380

CAATACTACA AGGTCCACCG GGCCCCAGGG GTCCAAGAGG TGACAGAGGA TCCCAGGGAC 1440
CCCCCTGGCCC AACTGGCAAC AAGGGACAGA AAGGAGAGAA GGGGAGCCT GGACCACCTG 1500
5 GCCCTGCGGG TGAGAGAGGC CCAATTGGAC CAGCTGGTCC CCCCAGAGAG CGTGGCGGCA 1560
AAGGATCTAA AGGCTCCCAG GGCCCCAAAG GCTCCCGTGG TTCCCTGGG AAGCCCGGCC 1620
10 CTCAGGGCCC CAGTGGGGAC CCAGGCCCCC CGGGCCCACC AGGCAAAGAG GGACTCCCCG 1680
GCCCTCAGGG CCTCCTGGC TTCCAGGGAC TTCAGGGCAC CGTTGGGGAG CCTGGGGTGC 1740
CTGGACCTCG GGGACTGCCA GGCTTGCTG GGGTACCAGG CATGCCAGGC CCCAAGGGCC 1800
15 CCCCCGGCCC TCCTGGCCCA TCAGGAGCGG TGGTGCCCCT GGCCCTGCAG AATGAGCCAA 1860
CCCCGGCACC GGAGGACAAT AGCTGCCCGC CTCCTGGAA GAACTTCACA GACAAATGCT 1920
20 ACTATTTTTC AGTTGAGAAA GAAATTTTTC AGGATGCAAA GCTTTTCTGT GAAGACAAGT 1980
CTTCACATCT TGTTTTCATA AACACTAGAG AGGAACAGCA ATGGATAAAA AACAGATGG 2040
TAGGGAGAGA GAGCCACTGG ATCGGCCTCA CAGACTCAGA GCGTGAAAAT GAATGGAAGT 2100
25 GGCTGGATGG GACATCTCCA GACTACAAAA ATTGGAAGC TGGACAGCCG GATAACTGGG 2160
GTCATGGCCA TGGGCCAGGA GAAGACTGTG CTGGGTTGAT TTATGCTGGG CAGTGAACG 2220
30 ATTTCCAATG TGAAGACGTC AATAACTTCA TTTGCGAAAA AGACAGGGAG ACAGTACTGT 2280
CATCTGCATT ATAACGGACT GTGATGGGAT CACATGAGCA AATTTTCAGC TCTCAAAGGC 2340
AAAGGACACT CCTTTCTAAT TGCATCACCT TCTCATCAGA TTGAAAAAAA AAAAGCACTG 2400
35 AAAGCCAATT ACTGAAAAAA AATTGACAGC TAGTGTTTTT TACCATCCGT CATTACCCAA 2460
AGACTTGGGA ACTAAAATGT TCCCCAGGGT GATATGCTGA TTTTCATTGT GCACATGGAC 2520
40 TGAATCACAT AGATTCTCCT CCGTCAGTAA CCGTGCGATT ATACAAATTA TGTCTTCCAA 2580
AGTATGGAAC ACTCCAATCA GAAAAAGGTT ATCATTGGTC GTTGAGTTAT GGGAAGAACT 2640
TAAGCATATA CTGTGTAAAC AGTGCCATAC ATTTCTAAAA TCCCAAGTGT AGGAAAAATA 2700
45 TGCAGACATA CAGATATATA GGCCAATAT TAGTAATAAT ATGAAATATA CTAAAGAGC 2760
TTTTAAACT TTGTATTTT GTACAAAATA TTTGTCTTTT ACAATTTTTT TCCTTTTTTT 2820
TTTTTTGTCA TTTTACCGAC ATAATACATG GAGCCAAAGA AAACAATAAT GGTACTAATA 2880
50 AAAACTCCTA GGGTTTCCTG TCAGATTTAA TTCTAAAAAA AAAAAAAAAA 2930

(2) INFORMATION FOR SEQ ID NO:12:

55 (1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 208 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: protein

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Lys Asp Asp Phe Ala Glu Glu Glu Val Gln Ser Phe Gly Tyr
 1 5 10 15
 Lys Arg Phe Gly Ile Gln Glu Gly Thr Gln Cys Thr Lys Cys Lys Asn
 20 25 30
 Asn Trp Ala Leu Lys Phe Ser Ile Ile Leu Leu Tyr Ile Leu Cys Ala
 35 40 45
 Leu Leu Thr Ile Thr Val Ala Ile Leu Gly Tyr Lys Val Val Glu Lys
 50 55 60
 Met Asp Asn Val Thr Gly Gly Met Glu Thr Ser Arg Gln Thr Tyr Asp
 65 70 75 80
 Asp Lys Leu Thr Ala Val Glu Ser Asp Leu Lys Lys Leu Gly Asp Gln
 85 90 95
 Thr Gly Lys Lys Ala Ile Ser Thr Asn Ser Glu Leu Ser Thr Phe Arg
 100 105 110
 Ser Asp Ile Leu Asp Leu Arg Gln Gln Leu Arg Glu Ile Thr Glu Lys
 115 120 125
 Thr Ser Lys Asn Lys Asp Thr Leu Glu Lys Leu Gln Ala Ser Gly Asp
 130 135 140
 Ala Leu Val Asp Arg Gln Ser Gln Leu Lys Glu Thr Leu Glu Asn Asn
 145 150 155 160
 Ser Phe Leu Ile Thr Thr Val Asn Lys Thr Leu Gln Ala Tyr Asn Gly
 165 170 175
 Tyr Val Thr Asn Leu Gln Gln Asp Thr Ser Val Leu Gln Gly Asn Leu
 180 185 190
 Gln Asn Gln Met Tyr Ser His Asn Val Val Ile Met Asn Ser Thr Thr
 195 200 205

50

(2) INFORMATION FOR SEQ ID NO:13:

55

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1589 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: cDNA

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

	TCTATATATT TTTTCTAGGA AGGGGTGTTT TTCTTTCTGA TTTAATTCCC TACATTTTTC	60
15	TCTTTCATAT GAAGTTGCAG ATAATGTTTT TCCTTCGGAT TTTTATTCTT TAAGATTTTT	120
	AACCTGTGCA AGACTTTTTT AATGATACAA GTCAAGGAGG ATGAAGATCT TTTTCCACTT	180
20	CAGTCTTCAC TTTGCTCCAG CTATTGCTAA GAAAGGCACA AACAATGACA GCATATTAA	240
	GGAAGAACCT GGCCGGCTTG GGTCAACCGT GCTGTCTTTC TTGGTTTTC GTCTACCTGG	300
	GAGAGCCCAG CTTTATAGGT CCCATTGAGG GAAGCATGAG AGAGGATTGT TTGGGGGATG	360
25	CTGCCAGAGC TTCCAGCTGA CAGTCTCTGC AGAGCGGCTG CCAAGTGCC TGGTGGCCGT	420
	ATGTTGGCAG TTTTGTATGA ATTGGGATTA GGAATGTTT GTTTACTTGA TAACCGAGTG	480
30	TCTACAAGGA GAGGTGGCAG CGTGAGGGAA TAGTGCCACC ATAATGAGGA CACAGCCAGC	540
	CATCTCTTCC CTGCCACAGA ACCCCAGGCA GTCCCCTTCA GGCTACAGTT TTCCATCTGG	600
	ACCGAGGGAC TGGCCGGTGC AGCAGGAGGA GCCGATCACC CTCTGTGGGA ACGAGGATGC	660
35	CCAGAAGTTC CAGTTACTGT GGCTCCATGG TCCCCTTCTC GATGCGCATC TTGCACGCGG	720
	AGCTTCAGCA GTACCTGGGG AACCACAGG AGTCGCTGGA TAGACTGCAC AAGGTGAAGA	780
40	CTGTCTGCAG CAAGATCCTG GCCAATTGAG AGCAAGGCTT AGCAGAAGAC GGCGGCATGA	840
	GCAGCGTGAC TCAGGAGGGC AGACAAGCCT CTATCCGGCT GTGGAGGTCA CGTCTGGGCC	900
	GGGTGATGTA CTCCATGGCA AACTGTCTGC TCCTGATGAA GGATTATGTG CTGGCCGTGG	960
45	AGGCGTATCA TTCGGTTATC AAGTATTACC CAGAGCAAGA GCCCCAGCTG CTCAGCGGCA	1020
	TCGGCCGGAT TTCCCTGCAG ATTGGAGACA TAAAAACAGC TGAAAAGTAT TTTCAAGACG	1080
50	TTGAGAAAGT AACACAGAAA TTAGATGGAC TACAGGGTAA AATCATGGTT TTGATGAACA	1140
	GCGCGTTCCT TCACCTCGGG CAGAATAACT TTGCAGAAGC CCACAGGTTC TTCACAGAGA	1200
	TCTTAAGGAT GGATCCAAGA AACGCAGTGG CCAACAACAA CGCTGCCGTG TGTCTGCTCT	1260
55	ACCTGGGCAA GCTCAAGGAC TCCCTGCGGC AGCTGGAGGC CATGGTCCAG CAGGACCCCA	1320

GGCACTACCT GCACGAGAGC GTGCTCTTCA ACCTGACCAC CATGTACGAG CTGGAGTCCT 1380
CACGGAGCAT GCAGAAGAAA CAGGCCCTGC TGGAGGCTGT CGCCGGCAAG GAGGGGGACA 1440
5 GCTTCAACAC ACAGTGCCTC AAGCTGGCCT AGCTGCCTCC AACACACTAC GTCAGAAGGA 1500
CCCCGGTCTT TGAAACTGTG TCTTGAAGCT AATGTATTAA TGTGACATGG AGGAACTCAA 1560
TAAAACTCCT GCTTCAAAAA AAAAAAAAAA 1589

10 (2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 271 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

25 Met Pro Arg Ser Ser Ser Tyr Cys Gly Ser Met Val Pro Phe Ser Met
1 5 10 15
30 Arg Ile Leu His Ala Glu Leu Gln Gln Tyr Leu Gly Asn Pro Gln Glu
20 25 30
Ser Leu Asp Arg Leu His Lys Val Lys Thr Val Cys Ser Lys Ile Leu
35 35 40 45
35 Ala Asn Leu Glu Gln Gly Leu Ala Glu Asp Gly Gly Met Ser Ser Val
50 55 60
40 Thr Gln Glu Gly Arg Gln Ala Ser Ile Arg Leu Trp Arg Ser Arg Leu
65 70 75 80
45 Gly Arg Val Met Tyr Ser Met Ala Asn Cys Leu Leu Leu Met Lys Asp
85 90 95
Tyr Val Leu Ala Val Glu Ala Tyr His Ser Val Ile Lys Tyr Tyr Pro
100 105 110
45 Glu Gln Glu Pro Gln Leu Leu Ser Gly Ile Gly Arg Ile Ser Leu Gln
115 120 125
50 Ile Gly Asp Ile Lys Thr Ala Glu Lys Tyr Phe Gln Asp Val Glu Lys
130 135 140
Val Thr Gln Lys Leu Asp Gly Leu Gln Gly Lys Ile Met Val Leu Met
145 150 155 160
55

Asn Ser Ala Phe Leu His Leu Gly Gln Asn Asn Phe Ala Glu Ala His
 165 170 175
 5 Arg Phe Phe Thr Glu Ile Leu Arg Met Asp Pro Arg Asn Ala Val Ala
 180 185 190
 Asn Asn Asn Ala Ala Val Cys Leu Leu Tyr Leu Gly Lys Leu Lys Asp
 195 200 205
 10 Ser Leu Arg Gln Leu Glu Ala Met Val Gln Gln Asp Pro Arg His Tyr
 210 215 220
 Leu His Glu Ser Val Leu Phe Asn Leu Thr Thr Met Tyr Glu Leu Glu
 225 230 235 240
 15 Ser Ser Arg Ser Met Gln Lys Lys Gln Ala Leu Leu Glu Ala Val Ala
 245 250 255
 20 Gly Lys Glu Gly Asp Ser Phe Asn Thr Gln Cys Leu Lys Leu Ala
 260 265 270

(2) INFORMATION FOR SEQ ID NO:15:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1153 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear
 30 (ii) MOLECULE TYPE: cDNA

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
 TATAAAGAGT GACTCTCCTA TGAAGGTAAA GGCCACCCCT CTTCA GTTCC AGTGACTGAG 60
 ATACATTTTT CCAATCCTGG GGGCAAATAC AGACACAGCA AGTTCCTTCT TCCCTTTGGA 120
 40 AATTTGGCAG CTGCCTTCAC CAGTGAGCAC AAAGCCACAT TTCAAAGGAA ACTGACAAAT 180
 TATCCCCAGC TGCCAGAAGA AGAAATCCTC ACTGGACGGC TTCCTGTTTC CTGTGGTTCA 240
 45 TTATCTGATT GGCTGCAGGG ATGAAAGTTT TTAAGTTCAT AGGACTGATG ATCCTCCTCA 300
 CCTCTGCGTT TTCAGCCGGT TCAGGACAAA GTCCAATGAC TGTGCTGTGC TCCATAGACT 360
 GGTTTCATGGT CACAGTGCAC CCCTTCATGC TAAACAACGA TGTGTGTGTA CACTTTCATG 420
 50 AACTACACTT GGGCCTGGGT TGCCCCCAA ACCATGTTCA GCCACACGCC TACCAGTTCA 480
 CCTACCGTGT TACTGAATGT GGCATCAGGG CCAAAGCTGT CTCTCAGGAC ATGGTTATCT 540
 55 ACAGCACTGA GATACACTAC TCTTCTAAGG GCACGCCATC TAAGTTTGTG ATCCCAGTGT 600

CATGTGCTGC CCCCCAAAAG TCCCCATGGC TCACCAAGCC CTGCTCCATG AGAGTAGCCA 660
 GCAAGAGCAG GGCCACAGCC CAGAAGGATG AGAAATGCTA CGAGGTGTTT AGCTTGTCAC 720
 5 AGTCCAGTCA AAGGCCCAAC TGCATTGTC CACCTTGTTT CTTCAGTGAA GAAGAGCATA 780
 CCCAGGTCCC TTGTACCAA GCAGGGGCTC AGGAGGCTCA ACCTCTGCAG CCATCTCACT 840
 TTCTTGATAT TTCTGAGGAT TGGTCTCTTC ACACAGATGA TATGATTGGG TCCATGTGAT 900
 10 CCTCAGGTTT GGGGTCTCCT GAAGATGCTA TTTCTAGAAT TAGTATATAG TGTACAAATG 960
 TCTGACAAAT AAGTGCTCTT GTGACCCTCA TGTGAGCACT TTTGAGAAAG AGAAACCTAT 1020
 15 AGCAACTTCA TGAATTAAGC CTTTTTCTAT ATTTTATAT TCATGTGTAA ACAAAAAATA 1080
 AAATAAAATT CTGATCGCAT AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1140
 AAAAAAAAAA AAA 1153

20 (2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 212 amino acids
 25 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

35 Met Lys Val Phe Lys Phe Ile Gly Leu Met Ile Leu Leu Thr Ser Ala
 1 5 10 15
 Phe Ser Ala Gly Ser Gly Gln Ser Pro Met Thr Val Leu Cys Ser Ile
 40 20 25 30
 Asp Trp Phe Met Val Thr Val His Pro Phe Met Leu Asn Asn Asp Val
 35 40 45
 45 Cys Val His Phe His Glu Leu His Leu Gly Leu Gly Cys Pro Pro Asn
 50 55 60
 His Val Gln Pro His Ala Tyr Gln Phe Thr Tyr Arg Val Thr Glu Cys
 65 70 75 80
 50 Gly Ile Arg Ala Lys Ala Val Ser Gln Asp Met Val Ile Tyr Ser Thr
 85 90 95
 Glu Ile His Tyr Ser Ser Lys Gly Thr Pro Ser Lys Phe Val Ile Pro
 55 100 105 110

Val Ser Cys Ala Ala Pro Gln Lys Ser Pro Trp Leu Thr Lys Pro Cys
 115 120 125
 5 Ser Met Arg Val Ala Ser Lys Ser Arg Ala Thr Ala Gln Lys Asp Glu
 130 135 140
 Lys Cys Tyr Glu Val Phe Ser Leu Ser Gln Ser Ser Gln Arg Pro Asn
 145 150 155 160
 10 Cys Asp Cys Pro Pro Cys Val Phe Ser Glu Glu Glu His Thr Gln Val
 165 170 175
 Pro Cys His Gln Ala Gly Ala Gln Glu Ala Gln Pro Leu Gln Pro Ser
 180 185 190
 15 His Phe Leu Asp Ile Ser Glu Asp Trp Ser Leu His Thr Asp Asp Met
 195 200 205
 20 Ile Gly Ser Met
 210

(2) INFORMATION FOR SEQ ID NO:17:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 4285 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear
 30 (ii) MOLECULE TYPE: cDNA

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TTTAATCTGT GTCTCCAGCA TTTATTTTTT TGTGTGTGTC ATCGGGTTCC TGGTTTTCTT 60
 TTAAGACATA GTCAACTGTG TGGACCTGTA GGTGTGGGGC AGCAACCAAT TCCATTGTTT 120
 40 TCCTTTTTGT CAAATCCAAG AGAAAATATA CCATAAGGAG CTAGAAGATT CTAGTTCACA 180
 GCCTTTTGAA TCTTCATGGC CTTTGAATCC TCATGGCCTC TGAAATCTGA ATCAGTTTTC 240
 45 TCCCAGGARG TCTCTGGGGG CTGAGCTGCT ACAGGGGCGAR ARGGTGGGGT GGGGTGGGT 300
 GGGARAATCA TCCTGGCACT TCATCGTGCA TGCTATTTTCG GGCAGCATCT TTTTTTTTTT 360
 ATTTTATTAT TATTTTTTTT CCTGATGCTT GAGTTATGAA TGAGGATGAC CTCTGCAATC 420
 50 ATGATGTCTC CCATAGACTC TGTCCTTGT TCCTTTGCCA GCTTCTCAT GCATGGTCCT 480
 AACACTTCCA TGATTTAATC TGCTGCAGGA CCATAGTCTT CAGCCACCTC AGCAATAACT 540
 55 TGTTAGAACA TTAAAAGGAA GTAAATTGAG AACAACTTGT TGCCATCCCA TTTTCATTAG 600

AAATCAGACA TCTTAGAGAT GTCAAGAAAG CAGCTAGCAG CTAGGGGGTA TGGGGACCTG 660
TCCTGCTCAC ACTGCTGTGT GTCAGACCAG ACCTGATCCT GGAGCTCAGG ACCCTAGAGA 720
5 GCCCTGATCT CTGGAACCTT TGCCACGTTG TTGCTGAGGC AGCTGAAGTC CCCATCTCCC 780
ACCATAACAA TCACAAATAG ACAGTAGTGG AGCCAGCATC CCCAGGCCCC TTTTGTGTGA 840
AGCAGAAAGG GAGCTGTGAG CCTTGCCCTG TTTGCAGGTG TCAAGTGCCT CTCCCTGCCT 900
10 GTACTTCTCC CCTTCCTCTG AGCAGAGCTT TGGTAGCTGT TGCCAATGCA AAGAAATGTA 960
AAGCAGCAAA AGAAGACAGC AGGTTCTGAC CTGAGGAGGG AAACCAAATT TATCCCACAA 1020
15 AGGCCCCATTA ACCCCACCCC CCTCGCCTCC CACCCCCAGA CTGGATCCAC TACTGGCCCCA 1080
AGAATACTGA TGAGAAACCT AGTCTGGATT GGGTCGGAAG CTGGAATTTG GTGCTCTGCA 1140
GACCAGTGCT CAAAATTGTG GTTATTTTGT AGGACTCGCC TTCAATCCAG AACATTTGCG 1200
20 TTTCACCTTC CTCGCCCAGA TCCAGTTAAC AAGGTAGCTC ATCACTTCTT GCATCTGTTG 1260
AGTGACATGC TGGATTTTAA TTTTATTGT GGTGTACTT GGATGCAAGG AATATGTTTT 1320
25 GTTCCTCCCA ATTTAGCGCA CCATCCTGGG AAGTGCATGT CTCAGACCAA CTCCACCTTC 1380
ACCTTCACCA CCTGTGCGAT CCTGCATCCT TCAGATGAGC TCACTCGGGT CACACCAAGC 1440
CTTAACTCAG CCCCAACTCC AGCTTGTGGC AGCACCAGCC ACTTGAAATC CACGCCGGTG 1500
30 GCCACACCAT GCACTCCACG GAGACTGAGC CTGGCTGAGT CCTTCACTAA CACCCGTGAG 1560
TCCACGACCA CCATGAGCAC ATCCCTGGGG CTCGTGTGGC TGTTGAAGGA GCGGGGCATT 1620
35 TCTGCTGCCG TGTACGACCC CCAGAGCTGG GACAGGGCCG GCCGGGGCTC CCTCCTGCAC 1680
TCCTACACGC CCAAGATGGC TGTGATCCCC TCTACTCCGC CGAACTCGCC TATGCAGACA 1740
CCCACATCCT CCCCACCCTC CTTTGAGTTC AAGTGCACGA GCCCTCCCTA CGACAATTTT 1800
40 CTGGCTTCCA AGCCAGCCAG CTCCATCCTG AGGGAAGTGA GAGAAAAGAA CGTCCGCAGC 1860
AGCGAGAGCC AGACCGACGT GTCCGTCTCC AACCTCAACC TCGTGGACAA AGTCAGGAGG 1920
45 TTTGGGGTGG CCAAAGTGGT GAACTCAGGG CGAGCCCATG TCCCCACCTT GACTGAGGAG 1980
CAGGGACCCC TCCTCTGTGG GCCCCGGGG CCAGCACCAG CCCTGTTCC CAGAGGCCTG 2040
GTACCTGAGG GCCTGCCCCT CAGATGCCCC ACTGTCACCA GTGCCATCGG TGGGCTGCAG 2100
50 CTCAATAGTG GCATCCGGCG GAATCGCAGC TTCCCCACCA TGGTGGGATC TAGCATGCAG 2160
ATGAAAGCTC CTGTGACTCT CACCTCGGGC ATCTTGATGG GTGCTAAGCT CTCCAAACAA 2220
55 ACTAGCTTAC GGTGAGGACT GGAGGGGGGC CGGTTGCCCT AGAGGAGACC CACGTTCTCT 2280

	CTTGCTCCCA CCTCCCTCTC TTCCCCCACC AGTGCACTCC CTCCCTCTGC CTTTCTCTGT	2340
	CCACCCCCTC CTAAGCTAGA CAAATCAACC TTGTGCCTAA TGGAGGAAGT GTGGAAACTT	2400
5	TGTAAATGT GTACATAGGA CTTGGAGACC TTGTGTCCGC CCTGCTCTTT CTTCGGATCC	2460
	CACAGGAAGT GCCCCTGCAC TGTCATCACT CTCACGAGGA CGTCACCTGT GCTAACCTGG	2520
10	GGGAAGGTGG GGTCTTTCT TCTTTCCTTT TGAGAAGCAC TGAAACTCCC AAGTGTGTTC	2580
	TTATCCCATG GATAGGAAAC CAGTGAATTC CGTGGCTGGC ACACCACGAG CTGTCATGCG	2640
	GCACGGGTCA TAACACATCT GGGTGTCACT GGACACCTCA CCTCGCCAC CCTGTAGGAG	2700
15	CGTAAGGAGC CTCCATCCTC AGCCACGTGC AGCTGACGTG GCTTTCCTGA TCGGAGGGCT	2760
	TTTCTTTTAT GGGTGGCCCA GCTTCTTCAA GACCTTCACT GCTCTGCCTC AGTGGACAGT	2820
20	CGTTTCTTTT TTGAGGTGTG ACCTTTTGTT TTCATGCCTT CCCCTTGAAG TCATCCTGTG	2880
	TTTTGTAATC AGCTGTCAGG CCAAATGTCT GACCCGAAAG AGAATGTATT TACACTCATG	2940
	CTGCGTTGTT CAGCAGCCCC TCTGTGTTCT GTGTGATTG TTTTATTTTT CTTTTTTTTT	3000
25	ACATATATAT GCAGGGAAGT AATGGTACTG GTAGTGTATG TTTTCTATGT GTTCAAATA	3060
	TGAATTTCTGA ACACACCAAG CCGCTAATGA GATAGCAGCT TTTTCTGGG ACCCAGAGTC	3120
30	ACAACCAAAT TGATTTAAGA CCGGACCCAA GACACCTTTA ACAATAGGAC TGAAAGGAAA	3180
	AAGGATAGGG AAAAAGCTTA TTAAAGAAAT GTGTCAACAC CAAATGTAGA GGGGAAGAAC	3240
	CACAACCAGG CATAATACCA AACCGGTTCC AGGGGGAAC AAGGCTTTGG TATTCCGCTG	3300
35	GCTCCAGCGC TTTTCTGAA ACCCGAGGCT GGCCAGGGTG CTGTCACCGT GTGGTCTTTG	3360
	ATTGCAGCCA TTCAATGCCC ACATGCTTTT CTTTCTTGTT TCAGAACAGC ACATGGTCAC	3420
40	AACAAGATAT TTTCTTTCCC TCCAAAGCCT TTTGTCTCCT TGTGCCTCTT TTTATCCTTA	3480
	GGAAAAGATC CAGGTGCTTG TGAAAAGAAT CATGAATGCA ACAAGGGAGG CTGGTCTGT	3540
	TGCTGTGCGC GATTAAGTTT TAACTTTTA TTTATTATTT ATGTCTGCCG TATTTTAAAT	3600
45	AAACATTCTC GTTCCTTCCA GTTCCAGTCA TAGTGTGTCT GTGGCATTCC AGTCCAACCA	3660
	TGTGACTTAT TTATTCTAAT TTGAGGGCTG CACTGTACAC CATGGTGTCC TGTGACACCG	3720
50	TGTTCCAGAC ATTTATGGAA GGAAAACATC CCATATAAAT GAAACTGTCA TGCTGTGTCC	3780
	TCCCCGGCAG CAGAAGATGT GTCCTTCCAT TGAGTGAGGG TAACCTTATG TCCACCAAGG	3840
	ATACTTTGAG AAAGCCCCTA AGGAACAAGC CTCAGTCCCA CGGTTTCAGA CTATTTATTC	3900
55	TCTGAACACA AGAGTATTGG TTAATTATGT TCTCAGCTCT CCCTGCTGTT GTATGTGTGC	3960

ATTCACTGCA AGTAACTTAT ATCTTTTTAT TTGAATGTAT TTAAAGCAG TAGATAGAAT 4020
 AACAAAGGAA TATGAAAACC ATGGACTGAA TGGACCATTT TATGTATTCA GAGAGAGAAG 4080
 5 CCACTCATCA TTGCCAGAAA TACCATGTAA AAATTGGCAG TTCAGAGGTT GCAATACTTA 4140
 GTATAGTAAA TAAATAAACG GTCAACATTG TGCAACCACT ACCAAAAAGT GTGTTGTAAT 4200
 GCATCAAAAA TCAACACAAT TTTATTCAT AATGAGTATC AATAAAATAA GTTCAAATGA 4260
 10 TGGAAACCAC AAAAAAAAAA AAAAA 4285

(2) INFORMATION FOR SEQ ID NO:18:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 429 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Met Gln Arg Asn Val Lys Gln Gln Lys Lys Thr Ala Gly Ser Asp Leu
 1 5 10 15
 30 Arg Arg Glu Thr Lys Phe Ile Pro Gln Arg Pro Ile Asn Pro Thr Pro
 20 25 30
 35 Leu Ala Ser His Pro Gln Thr Gly Ser Thr Thr Gly Pro Arg Ile Leu
 35 40 45
 Met Arg Asn Leu Val Trp Ile Gly Ser Glu Ala Gly Ile Trp Cys Ser
 50 55 60
 40 Ala Asp Gln Cys Ser Lys Leu Trp Leu Phe Leu Arg Thr Arg Leu Gln
 65 70 75 80
 Ser Arg Thr Phe Ala Phe His Leu Pro Arg Pro Asp Pro Val Asn Lys
 85 90 95
 45 Val Ala His His Phe Leu His Leu Leu Ser Asp Met Leu Asp Phe Asn
 100 105 110
 Phe Tyr Cys Gly Cys Thr Trp Met Gln Gly Ile Cys Phe Val Pro Pro
 115 120 125
 50 Asn Leu Ala His His Pro Gly Lys Cys Met Ser Gln Thr Asn Ser Thr
 130 135 140
 55 Phe Thr Phe Thr Thr Cys Arg Ile Leu His Pro Ser Asp Glu Leu Thr

145 150 155 160
 Arg Val Thr Pro Ser Leu Asn Ser Ala Pro Thr Pro Ala Cys Gly Ser
 165 170 175
 5 Thr Ser His Leu Lys Ser Thr Pro Val Ala Thr Pro Cys Thr Pro Arg
 180 185 190
 10 Arg Leu Ser Leu Ala Glu Ser Phe Thr Asn Thr Arg Glu Ser Thr Thr
 195 200 205
 Thr Met Ser Thr Ser Leu Gly Leu Val Trp Leu Leu Lys Glu Arg Gly
 210 215 220
 15 Ile Ser Ala Ala Val Tyr Asp Pro Gln Ser Trp Asp Arg Ala Gly Arg
 225 230 235 240
 Gly Ser Leu Leu His Ser Tyr Thr Pro Lys Met Ala Val Ile Pro Ser
 245 250 255
 20 Thr Pro Pro Asn Ser Pro Met Gln Thr Pro Thr Ser Ser Pro Pro Ser
 260 265 270
 25 Phe Glu Phe Lys Cys Thr Ser Pro Pro Tyr Asp Asn Phe Leu Ala Ser
 275 280 285
 Lys Pro Ala Ser Ser Ile Leu Arg Glu Val Arg Glu Lys Asn Val Arg
 290 295 300
 30 Ser Ser Glu Ser Gln Thr Asp Val Ser Val Ser Asn Leu Asn Leu Val
 305 310 315 320
 Asp Lys Val Arg Arg Phe Gly Val Ala Lys Val Val Asn Ser Gly Arg
 325 330 335
 35 Ala His Val Pro Thr Leu Thr Glu Glu Gln Gly Pro Leu Leu Cys Gly
 340 345 350
 40 Pro Pro Gly Pro Ala Pro Ala Leu Val Pro Arg Gly Leu Val Pro Glu
 355 360 365
 Gly Leu Pro Leu Arg Cys Pro Thr Val Thr Ser Ala Ile Gly Gly Leu
 370 375 380
 45 Gln Leu Asn Ser Gly Ile Arg Arg Asn Arg Ser Phe Pro Thr Met Val
 385 390 395 400
 Gly Ser Ser Met Gln Met Lys Ala Pro Val Thr Leu Thr Ser Gly Ile
 405 410 415
 50 Leu Met Gly Ala Lys Leu Ser Lys Gln Thr Ser Leu Arg
 420 425

55 (2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3751 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ACTTTGAATT TTTTATTTGT GAAATTAAAA ATATGGTATT ATATATATAT AAACCTTCTAT 60
TCCTCTATAA ATATAGATGA TTTTGTGATA GTGAACAGAA TAAATGTATA CCAAATTCAA 120
AGACCAATAT CATTTTAGCG TATGACAGAC ATAGATAAAT TTAGGTCCTA AGTACCGGCA 180
TTTTGATAAA TTCTTAAAGT TTAACAAT ACAATCAGGA GGATTGCTTT TCTCCTCTTC 240
TTCACAGAGA ACTAAAGTGA ATATTTTAA ATGGCTTTGA AAGATTACA TTTGACACAT 300
TTCTGTAAAT CCAAAGAGG AGCACACAGG GATTAAATGC AGTAGACCTG CACACATTTT 360
CCCTTTAGCA TGCATGCCCA TATTTTGTTC ATTTTCAGGCG CTATCTCCCC GTCAATTATT 420
CCACCTTCTT TACCTCCTGA AATCTTACCA GGTTATTATT GGTGGTGTGA ATTGTTCCCC 480
CCTCAGAATG TGCTGCTGAA TAATAATCGT AATAAAATGT TGAAAGTGTA CAACTTTTAC 540
ATTTTAAAGT TTCTGATATA TGTCTAGTTA TTTGATTAAA AATAAGAAAA TAGCACTTCA 600
TTTTGAGGAA GTCCATGACA CTGAAATATC CTTCAAGTTT TCAATTCTG TTTACGTTTT 660
GCTGTCTTGT TAAGGAAAGC AACATCAAC TCCTTAACAA AGCTTTCCAG GTGACCTCAA 720
CATTTCCATT TTACAGACCG GTAAATCTA AGCGCAGGCT GTCTCATTCT CAAAGGCAAG 780
GTTGCCAGGC ATCCGTATGC AATTAGAATT AACATTTTAT AACCCATATC TTCAGTCTCT 840
TCCAACCCAC ACAAAGCTTC ATGCTTCTTC CCAAATCTCA GTAACCACAT CTTTCCATGA 900
CGCTGGCCAA ACCCATACCA GGTTTTAGAC ACTAGAGAAT GAAATGAGCT CACCCCTCAA 960
AAATTAGACT TCAAAAAGTT TGGCATTGGT TATCTCACTC ACCCTGTAAC CAACTAAGGT 1020
GGGAGAAGGG AGTGTCTGGC GTTGAAGGTG ACCGTGGAGG GAGGCTGAGA CTGCCAGCGC 1080
CCACACCCGT GGGCCCCCAT GAAGTTGGAG GAAAGTTCTG GACAGTTAAA AATCCAGCTT 1140
CAGGAAGTCG AAGGGACGGG CCTTCGCAAT CCACCGCCGA GCAAGGGAGG AATTGTAATG 1200
TATGGGGGCC CTCCTCCAGA TTTGGAAGGT TTGTGGAGTT CTGTACCTTA AGAGCCCCTA 1260

CCTCAAGCCA GGAAAGAAAG GGAGGGGACA GAAGGAGGGG GAGGGGGCAA AAGGAGGAGG 1320
CGGGAAGTGA CCCTGGCAGC GCAGCCCTAG TCGCACCCCG CAGTGCTGAA CTCGCCCCGG 1380
5 AGCTGGCGCC CAGCCGTCCC GAGCACCCGT GGTAGGGAGA GGC GCGCAG GACGACCAGG 1440
AGCGCTGTGC GGTGACACAC CAGTTTTAGC TCCTTTGCAA TACTCCGAAA AGGGCAAGAA 1500
10 GAAAAGCCTC AAATGGTTAA ACCGCCCTAA ATAATTAAAA ACTTTTGAAA AAGAAAAACG 1560
CGTGATCGGT CGTCATTTAA ATACAAATAT ACTTACAAAA ATCCTACACA GGCTATTTAC 1620
AATCATAAAA GCGAACAGTC CTGGTACCAG AGTGTGAGGG CAAGAGGTCT GTCCATCCTC 1680
15 CCTCTGGCAG TCGGGCCCTC GTGTCCTTTT GCCTCAGGGA CGGAAGCTTT TGCAGGAGCT 1740
GAGTTGTTCT AGGCCTCTTT GGCCGAATTC GGCCAAAGAG GCCTAATTCC TTCCTCGGTT 1800
20 ATTTCAATTCA GAGAATATTT ATGAAATGCC TACTGTGTGC AAGTCATCCA TCCTTGAAAA 1860
GGCCACTTCT CAGTGAGGGA GAGATGTAGT GGATTCTGTG AGACATACCT GCTGGAGTTG 1920
AAGCAGTAAA TAGCATGTCT TTCCCCTCCC CGATCTTAAG GTGTGTTTTT TAGAAAAGTT 1980
25 CCCTAATGGA ATTCATGAGT TTGGGGGTCT CAGTCACCCG CTTGCCTGTA GGATTCCATT 2040
TGATGATTCT GGATTTTTGC TGTGTGTTAT TGCCCTTAGA GGGGCTCTGA GTATCTACTT 2100
GTGGGTGGCC ATTTCTGAC ATCTGCATGT ACCTCGTGGA ATTCAGCCAG CTTCATGTTG 2160
30 CAAATCAGAA AGCTGACCCC AAGACTGCAA ATCAATGAAG GTATTGGCAT TGTTAAGGTC 2220
GTAGCGTAGA CAACAGCAGT CATAAATAAT TAGGCAGGAA CTTAACCCAA ATCTAGTTCT 2280
35 TTGACCACCT CTACCACCAG AACCAGCAG AACTCACAT CTCCTGATAA GAGTTGCTGG 2340
ACTCGATGTT TTTGTTTTGC ATTTCTCCT CTCCTTCCCC ACTTACTCAG AGAATTTAAA 2400
GTCTGTAGAG TCAGCACAGC CCCATCAGTC CAGGAACTTC CCACCACCAG CCCTTGACTG 2460
40 TCCCATTAACT TGACATGGTC AGATTTCCAG CTCCCCTAC TCCCTGCTGT GAAACAATCC 2520
CTCTCCYTGT GAGAGGAAAY TCGCGSGAA GGYTAAGGGA GTGTGGCGGG CGGYTCCGGG 2580
45 AGCCAACATG CCTCGGTATG CGCAGCTGKT CATGGSCCCC GCGGGCAGCG GGAAGAGCAC 2640
YTAGTGTGCC ACCATGGTCC AGCACTGTGA AGCCYTCAAC CGGTCTGTCC AAGTTGTAAA 2700
50 CCTGGATCCA GCAGCAGAAC ACTTCAAYTA CTCCGTGATG GCTGACATCC GGGAAGTATG 2760
CGAGGTGGAT GATGTAATGG AGGATGATTY TYTGCGATTC GGTCCCAACG GAGGATTGGT 2820
ATTTTGCATG GAGTACTTTG CCAATAATTT TGAAGGCTG GAGAACTGTC TTGGCCATGT 2880
55 AGAGGACGAC TATATCCTTT TTGATTGTCC AGGTCAGATT GAGTTGTACA CTCACCTGCC 2940

TGTGATGAAA CAGCTGGTCC AGCAGCTCGA GCAGTGGGAG TTCCGAGTCT GTGGAATTTT 3000
 TYTTGTTGAT TCTCAGTTCA TGGTGGAGTC ATTCAAGTTT ATTTCTGGCA TCTTGGCAGC 3060
 5 CCTGAGTGCC ATGATCTCTC TAGAAATTCC GCAAGTCAAC ATCATGACAA AAATGGATCT 3120
 GCTGAGTAAA AAAGCAAAAA AGGAAATTGA GAAATTTTGA GATCCAGACA TGTATTCTTT 3180
 ATTAGAAGAT TCTACAAGTG ACTTAAGAAG CAAAAAATTC AAGAACTGA CTAAAGCTAT 3240
 10 ATGTGGACTG ATTGATGACT ACAGCATGGT TCGATTTTGA CCTTACGATC AGTCAGATGA 3300
 AGAAAGCATG AACATTGTAT TGCAGCATAT TGATTTTGCC ATTCAATATG GAGAAGACCT 3360
 15 AGAATTTAAA GAACCAAAGG AACGTGAAGA TGAGTCTTCC TCTATGTTTG ACGAATATTT 3420
 TCAAGAATGC CAGGATGAAT GAAGAGTTTA CTAAAAGTAA CCATCTAAAG AGCTTGTTGGC 3480
 CAAACCAGCA GAACATTCTT CTYTTCAAAG GATGCAATAG TAGAAAGCTA CTTATTTTAA 3540
 20 TGAAAAAAAG TAAACTTTCG TTCTTTATCA GCCTCATGCC TGAATCAAAT TTTTAATTAT 3600
 TCTGAACTG CTGCTGTTTA AAGTGAATC TTTTAGTATT ATAACAGCAT CACTTTAGAT 3660
 25 TTTGTAAGTC AAAATTGAAA TGAATGCACA TAGATTTATA TATAAATTAG CACCTGAGCT 3720
 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA A 3751

(2) INFORMATION FOR SEQ ID NO:20:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 284 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

35

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

45 Met Pro Arg Tyr Ala Gln Leu Xaa Met Xaa Pro Ala Gly Ser Gly Lys
 1 5 10 15
 Ser Thr Tyr Cys Ala Thr Met Val Gln His Cys Glu Ala Xaa Asn Arg
 20 25 30
 50 Ser Val Gln Val Val Asn Leu Asp Pro Ala Ala Glu His Phe Asn Tyr
 35 40 45
 Ser Val Met Ala Asp Ile Arg Glu Leu Ile Glu Val Asp Asp Val Met
 50 55 60
 55

5 Glu Asp Asp Xaa Leu Arg Phe Gly Pro Asn Gly Gly Leu Val Phe Cys
 65 70 75 80
 10 Met Glu Tyr Phe Ala Asn Asn Phe Asp Trp Leu Glu Asn Cys Leu Gly
 85 90 95
 15 His Val Glu Asp Asp Tyr Ile Leu Phe Asp Cys Pro Gly Gln Ile Glu
 100 105 110
 20 Leu Tyr Thr His Leu Pro Val Met Lys Gln Leu Val Gln Gln Leu Glu
 115 120 125
 25 Gln Trp Glu Phe Arg Val Cys Gly Xaa Xaa Xaa Val Asp Ser Gln Phe
 130 135 140
 30 Met Val Glu Ser Phe Lys Phe Ile Ser Gly Ile Leu Ala Ala Leu Ser
 145 150 155 160
 35 Ala Met Ile Ser Leu Glu Ile Pro Gln Val Asn Ile Met Thr Lys Met
 165 170 175
 40 Asp Leu Leu Ser Lys Lys Ala Lys Lys Glu Ile Glu Lys Phe Leu Asp
 180 185 190
 45 Pro Asp Met Tyr Ser Leu Leu Glu Asp Ser Thr Ser Asp Leu Arg Ser
 195 200 205
 50 Lys Lys Phe Lys Lys Leu Thr Lys Ala Ile Cys Gly Leu Ile Asp Asp
 210 215 220
 55 Tyr Ser Met Val Arg Phe Leu Pro Tyr Asp Gln Ser Asp Glu Glu Ser
 225 230 235 240
 60 Met Asn Ile Val Leu Gln His Ile Asp Phe Ala Ile Gln Tyr Gly Glu
 245 250 255
 65 Asp Leu Glu Phe Lys Glu Pro Lys Glu Arg Glu Asp Glu Ser Ser Ser
 260 265 270
 70 Met Phe Asp Glu Tyr Phe Gln Glu Cys Gln Asp Glu
 275 280

(2) INFORMATION FOR SEQ ID NO:21:

- 45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 29 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 50 (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "oligonucleotide"
 55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

TNCAGGCCTT GCGTTCCTAG CTGCTCTGC

29

5 (2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

10 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "oligonucleotide"

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

20

GNGCTGTGAG TTTATCCACA AAGGAACAG

29

(2) INFORMATION FOR SEQ ID NO:23:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "oligonucleotide"

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GNATAGGAGG TCCCAAGTTA TCAAGGTTT

40

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

45 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

50

(A) DESCRIPTION: /desc = "oligonucleotide"

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GNTTTCCTGG TTCTTGGTCA GGTTTCCTC

29

(2) INFORMATION FOR SEQ ID NO:25:

5

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

10

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

20 CNAGATGCAA TGGTTGTGAG ATTGACCAA

29

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

25

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

35 GNCACTTTCC ACTGCTGTGA GCTTGTCAT

29

(2) INFORMATION FOR SEQ ID NO:27:

40

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

45

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

55 ANCAGACAGT TTGCCATGGA GTACATCAC

29

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

TNATGAACCA CAGGAAACAG GAAGCCGTC

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

TNAAGGTGAA GGTGGAGTTG GTCTGAGAC

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GNCAGAAATA AACTTGAATG ACTCCACCA

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 457 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

15 Met Asn Ser Gln Leu Asn Ser Phe Thr Gly Gln Met Glu Asn Ile Thr
 1 5 10 15
 Thr Ile Ser Gln Ala Asn Glu Gln Asn Leu Lys Asp Leu Gln Asp Leu
 20 25 30
 His Lys Asp Ala Glu Asn Arg Thr Ala Ile Lys Phe Asn Gln Leu Glu
 35 40 45
 Glu Arg Phe Gln Leu Phe Glu Thr Asp Ile Val Asn Ile Ile Ser Asn
 50 55 60
 25 Ile Ser Tyr Thr Ala His His Leu Arg Thr Leu Thr Ser Asn Leu Asn
 65 70 75 80
 Glu Val Arg Thr Thr Cys Thr Asp Thr Leu Thr Lys His Thr Asp Asp
 85 90 95
 30 Leu Thr Ser Leu Asn Asn Thr Leu Ala Asn Ile Arg Leu Asp Ser Val
 100 105 110
 Ser Leu Arg Met Gln Gln Asp Leu Met Arg Ser Arg Leu Asp Thr Glu
 115 120 125
 Val Ala Asn Leu Ser Val Ile Met Glu Glu Met Lys Leu Val Asp Ser
 130 135 140
 40 Lys His Gly Gln Leu Ile Lys Asn Phe Thr Ile Leu Gln Gly Pro Pro
 145 150 155 160
 Gly Pro Arg Gly Pro Arg Gly Asp Arg Gly Ser Gln Gly Pro Pro Gly
 165 170 175
 45 Pro Thr Gly Asn Lys Gly Gln Lys Gly Glu Lys Gly Glu Pro Gly Pro
 180 185 190
 50 Pro Gly Pro Ala Gly Glu Arg Gly Pro Ile Gly Pro Ala Gly Pro Pro
 195 200 205
 Gly Glu Arg Gly Gly Lys Gly Ser Lys Gly Ser Gln Gly Pro Lys Gly
 210 215 220

Ser Arg Gly Ser Pro Gly Lys Pro Gly Pro Gln Gly Pro Ser Gly Asp
 225 230 235 240
 5 Pro Gly Pro Pro Gly Pro Pro Gly Lys Glu Gly Leu Pro Gly Pro Gln
 245 250 255
 Gly Pro Pro Gly Phe Gln Gly Leu Gln Gly Thr Val Gly Glu Pro Gly
 260 265 270
 10 Val Pro Gly Pro Arg Gly Leu Pro Gly Leu Pro Gly Val Pro Gly Met
 275 280 285
 Pro Gly Pro Lys Gly Pro Pro Gly Pro Pro Gly Pro Ser Gly Ala Val
 290 295 300
 15 Val Pro Leu Ala Leu Gln Asn Glu Pro Thr Pro Ala Pro Glu Asp Asn
 305 310 315 320
 Ser Cys Pro Pro His Trp Lys Asn Phe Thr Asp Lys Cys Tyr Tyr Phe
 325 330 335
 Ser Val Glu Lys Glu Ile Phe Glu Asp Ala Lys Leu Phe Cys Glu Asp
 340 345 350
 25 Lys Ser Ser His Leu Val Phe Ile Asn Thr Arg Glu Glu Gln Gln Trp
 355 360 365
 Ile Lys Lys Gln Met Val Gly Arg Glu Ser His Trp Ile Gly Leu Thr
 370 375 380
 30 Asp Ser Glu Arg Glu Asn Glu Trp Lys Trp Leu Asp Gly Thr Ser Pro
 385 390 395 400
 Asp Tyr Lys Asn Trp Lys Ala Gly Gln Pro Asp Asn Trp Gly His Gly
 405 410 415
 35 His Gly Pro Gly Glu Asp Cys Ala Gly Leu Ile Tyr Ala Gly Gln Trp
 420 425 430
 40 Asn Asp Phe Gln Cys Glu Asp Val Asn Asn Phe Ile Cys Glu Lys Asp
 435 440 445
 Arg Glu Thr Val Leu Ser Ser Ala Leu
 450 455

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 542 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

5 Cys Gly His His Glu Leu Asn Asn Leu Asn Leu Thr Gln Val Gln Gln
 1 5 10 15
 Arg Asn Leu Ile Thr Asn Leu Gln Arg Ser Val Asp Asp Thr Ser Gln
 10 20 25 30
 Ala Ile Gln Arg Ile Lys Asn Asp Phe Gln Asn Leu Gln Gln Val Phe
 35 40 45
 15 Leu Gln Ala Lys Lys Asp Thr Asp Trp Leu Lys Glu Lys Val Gln Ser
 50 55 60
 Leu Gln Thr Leu Ala Ala Asn Asn Ser Ala Leu Ala Lys Ala Asn Asn
 65 70 75 80
 20 Asp Thr Leu Glu Asp Met Asn Ser Gln Leu Asn Ser Phe Thr Gly Gln
 85 90 95
 Met Glu Asn Ile Thr Thr Ile Ser Gln Ala Asn Glu Gln Asn Leu Lys
 100 105 110
 25 Asp Leu Gln Asp Leu His Lys Asp Ala Glu Asn Arg Thr Ala Ile Lys
 115 120 125
 Phe Asn Gln Leu Glu Glu Arg Phe Gln Leu Phe Glu Thr Asp Ile Val
 130 135 140
 Asn Ile Ile Ser Asn Ile Ser Tyr Thr Ala His His Leu Arg Thr Leu
 145 150 155 160
 35 Thr Ser Asn Leu Asn Glu Val Arg Thr Thr Cys Thr Asp Thr Leu Thr
 165 170 175
 Lys His Thr Asp Asp Leu Thr Ser Leu Asn Asn Thr Leu Ala Asn Ile
 180 185 190
 40 Arg Leu Asp Ser Val Ser Leu Arg Met Gln Gln Asp Leu Met Arg Ser
 195 200 205
 Arg Leu Asp Thr Glu Val Ala Asn Leu Ser Val Ile Met Glu Glu Met
 210 215 220
 45 Lys Leu Val Asp Ser Lys His Gly Gln Leu Ile Lys Asn Phe Thr Ile
 225 230 235 240
 50 Leu Gln Gly Pro Pro Gly Pro Arg Gly Pro Arg Gly Asp Arg Gly Ser
 245 250 255
 Gln Gly Pro Pro Gly Pro Thr Gly Asn Lys Gly Gln Lys Gly Glu Lys
 260 265 270
 55

109

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 266 to nucleotide 1651;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 521 to nucleotide 1651;
 - (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 335 to nucleotide 634;
 - (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone as294_3 deposited under accession number ATCC 98444;
 - (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone as294_3 deposited under accession number ATCC 98444;
 - (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone as294_3 deposited under accession number ATCC 98444;
 - (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone as294_3 deposited under accession number ATCC 98444;
 - (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
 - (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
 - (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
 - (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
 - (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.

Ser Arg Gly Ser Pro Gly Lys Pro Gly Pro Gln Gly Pro Ser Gly Asp
 225 230 235 240
 5 Pro Gly Pro Pro Gly Pro Pro Gly Lys Glu Gly Leu Pro Gly Pro Gln
 245 250 255
 Gly Pro Pro Gly Phe Gln Gly Leu Gln Gly Thr Val Gly Glu Pro Gly
 260 265 270
 10 Val Pro Gly Pro Arg Gly Leu Pro Gly Leu Pro Gly Val Pro Gly Met
 275 280 285
 Pro Gly Pro Lys Gly Pro Pro Gly Pro Pro Gly Pro Ser Gly Ala Val
 290 295 300
 15 Val Pro Leu Ala Leu Gln Asn Glu Pro Thr Pro Ala Pro Glu Asp Asn
 305 310 315 320
 Ser Cys Pro Pro His Trp Lys Asn Phe Thr Asp Lys Cys Tyr Tyr Phe
 325 330 335
 Ser Val Glu Lys Glu Ile Phe Glu Asp Ala Lys Leu Phe Cys Glu Asp
 340 345 350
 25 Lys Ser Ser His Leu Val Phe Ile Asn Thr Arg Glu Glu Gln Gln Trp
 355 360 365
 Ile Lys Lys Gln Met Val Gly Arg Glu Ser His Trp Ile Gly Leu Thr
 370 375 380
 30 Asp Ser Glu Arg Glu Asn Glu Trp Lys Trp Leu Asp Gly Thr Ser Pro
 385 390 395 400
 Asp Tyr Lys Asn Trp Lys Ala Gly Gln Pro Asp Asn Trp Gly His Gly
 405 410 415
 His Gly Pro Gly Glu Asp Cys Ala Gly Leu Ile Tyr Ala Gly Gln Trp
 420 425 430
 40 Asn Asp Phe Gln Cys Glu Asp Val Asn Asn Phe Ile Cys Glu Lys Asp
 435 440 445
 Arg Glu Thr Val Leu Ser Ser Ala Leu
 450 455

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 542 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

5 Cys Gly His His Glu Leu Asn Asn Leu Asn Leu Thr Gln Val Gln Gln
 1 5 10 15
 Arg Asn Leu Ile Thr Asn Leu Gln Arg Ser Val Asp Asp Thr Ser Gln
 20 25 30
 10 Ala Ile Gln Arg Ile Lys Asn Asp Phe Gln Asn Leu Gln Gln Val Phe
 35 40 45
 Leu Gln Ala Lys Lys Asp Thr Asp Trp Leu Lys Glu Lys Val Gln Ser
 50 55 60
 Leu Gln Thr Leu Ala Ala Asn Asn Ser Ala Leu Ala Lys Ala Asn Asn
 65 70 75 80
 20 Asp Thr Leu Glu Asp Met Asn Ser Gln Leu Asn Ser Phe Thr Gly Gln
 85 90 95
 Met Glu Asn Ile Thr Thr Ile Ser Gln Ala Asn Glu Gln Asn Leu Lys
 100 105 110
 25 Asp Leu Gln Asp Leu His Lys Asp Ala Glu Asn Arg Thr Ala Ile Lys
 115 120 125
 Phe Asn Gln Leu Glu Glu Arg Phe Gln Leu Phe Glu Thr Asp Ile Val
 130 135 140
 Asn Ile Ile Ser Asn Ile Ser Tyr Thr Ala His His Leu Arg Thr Leu
 145 150 155 160
 35 Thr Ser Asn Leu Asn Glu Val Arg Thr Thr Cys Thr Asp Thr Leu Thr
 165 170 175
 Lys His Thr Asp Asp Leu Thr Ser Leu Asn Asn Thr Leu Ala Asn Ile
 180 185 190
 40 Arg Leu Asp Ser Val Ser Leu Arg Met Gln Gln Asp Leu Met Arg Ser
 195 200 205
 Arg Leu Asp Thr Glu Val Ala Asn Leu Ser Val Ile Met Glu Glu Met
 210 215 220
 Lys Leu Val Asp Ser Lys His Gly Gln Leu Ile Lys Asn Phe Thr Ile
 225 230 235 240
 50 Leu Gln Gly Pro Pro Gly Pro Arg Gly Pro Arg Gly Asp Arg Gly Ser
 245 250 255
 Gln Gly Pro Pro Gly Pro Thr Gly Asn Lys Gly Gln Lys Gly Glu Lys
 260 265 270
 55

Gly Glu Pro Gly Pro Pro Gly Pro Ala Gly Glu Arg Gly Pro Ile Gly
 275 280 285
 5 Pro Ala Gly Pro Pro Gly Glu Arg Gly Gly Lys Gly Ser Lys Gly Ser
 290 295 300
 Gln Gly Pro Lys Gly Ser Arg Gly Ser Pro Gly Lys Pro Gly Pro Gln
 305 310 315 320
 10 Gly Pro Ser Gly Asp Pro Gly Pro Pro Gly Pro Pro Gly Lys Glu Gly
 325 330 335
 Leu Pro Gly Pro Gln Gly Pro Pro Gly Phe Gln Gly Leu Gln Gly Thr
 340 345 350
 15 Val Gly Glu Pro Gly Val Pro Gly Pro Arg Gly Leu Pro Gly Leu Pro
 355 360 365
 Gly Val Pro Gly Met Pro Gly Pro Lys Gly Pro Pro Gly Pro Pro Gly
 370 375 380
 20 Pro Ser Gly Ala Val Val Pro Leu Ala Leu Gln Asn Glu Pro Thr Pro
 385 390 395 400
 25 Ala Pro Glu Asp Asn Ser Cys Pro Pro His Trp Lys Asn Phe Thr Asp
 405 410 415
 Lys Cys Tyr Tyr Phe Ser Val Glu Lys Glu Ile Phe Glu Asp Ala Lys
 420 425 430
 30 Leu Phe Cys Glu Asp Lys Ser Ser His Leu Val Phe Ile Asn Thr Arg
 435 440 445
 Glu Glu Gln Gln Trp Ile Lys Lys Gln Met Val Gly Arg Glu Ser His
 450 455 460
 35 Trp Ile Gly Leu Thr Asp Ser Glu Arg Glu Asn Glu Trp Lys Trp Leu
 465 470 475 480
 40 Asp Gly Thr Ser Pro Asp Tyr Lys Asn Trp Lys Ala Gly Gln Pro Asp
 485 490 495
 Asn Trp Gly His Gly His Gly Pro Gly Glu Asp Cys Ala Gly Leu Ile
 500 505 510
 45 Tyr Ala Gly Gln Trp Asn Asp Phe Gln Cys Glu Asp Val Asn Asn Phe
 515 520 525
 50 Ile Cys Glu Lys Asp Arg Glu Thr Val Leu Ser Ser Ala Leu
 530 535 540

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 266 to nucleotide 1651;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 521 to nucleotide 1651;
 - (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 335 to nucleotide 634;
 - (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone as294_3 deposited under accession number ATCC 98444;
 - (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone as294_3 deposited under accession number ATCC 98444;
 - (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone as294_3 deposited under accession number ATCC 98444;
 - (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone as294_3 deposited under accession number ATCC 98444;
 - (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
 - (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
 - (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
 - (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
 - (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.

3. A host cell transformed with the polynucleotide of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:
 - (a) growing a culture of the host cell of claim 3 in a suitable culture medium; and
 - (b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.
7. A protein comprising an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:2;
 - (b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 123;
 - (c) fragments of the amino acid sequence of SEQ ID NO:2 comprising eight consecutive amino acids of SEQ ID NO:2; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone as294_3 deposited under accession number ATCC 98444;the protein being substantially free from other mammalian proteins.
8. The protein of claim 7, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
9. The protein of claim 7, wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 123.
10. A composition comprising the protein of claim 7 and a pharmaceutically acceptable carrier.
11. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:1.

12. An isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 262 to nucleotide 3096;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 1118 to nucleotide 1527;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone aw92_1 deposited under accession number ATCC 98444;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone aw92_1 deposited under accession number ATCC 98444;
 - (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone aw92_1 deposited under accession number ATCC 98444;
 - (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone aw92_1 deposited under accession number ATCC 98444;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
 - (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
13. A protein comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:4;
 - (b) the amino acid sequence of SEQ ID NO:4 from amino acid 287 to amino acid 422;

- (c) fragments of the amino acid sequence of SEQ ID NO:4 comprising eight consecutive amino acids of SEQ ID NO:4; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone aw92_1 deposited under accession number ATCC 98444;
- the protein being substantially free from other mammalian proteins.

14. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:3.
15. An isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 612 to nucleotide 806;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 744 to nucleotide 806;
 - (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 1 to nucleotide 794;
 - (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bd316_2 deposited under accession number ATCC 98444;
 - (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bd316_2 deposited under accession number ATCC 98444;
 - (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bd316_2 deposited under accession number ATCC 98444;
 - (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bd316_2 deposited under accession number ATCC 98444;
 - (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
 - (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:6;
 - (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
 - (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).
16. A protein comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:6;
 - (b) the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 61;
 - (c) fragments of the amino acid sequence of SEQ ID NO:6 comprising eight consecutive amino acids of SEQ ID NO:6; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone bd316_2 deposited under accession number ATCC 98444;
- the protein being substantially free from other mammalian proteins.
17. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:5.
18. An isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 7 to nucleotide 300;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 1 to nucleotide 363;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bk130_4 deposited under accession number ATCC 98444;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bk130_4 deposited under accession number ATCC 98444;
 - (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bk130_4 deposited under accession number ATCC 98444;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bk130_4 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:8;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

19. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:8;

(b) fragments of the amino acid sequence of SEQ ID NO:8 comprising eight consecutive amino acids of SEQ ID NO:8; and

(c) the amino acid sequence encoded by the cDNA insert of clone bk130_4 deposited under accession number ATCC 98444;

the protein being substantially free from other mammalian proteins.

20. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:7.

21. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 52 to nucleotide 1863;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 1219 to nucleotide 1863;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 1099 to nucleotide 1743;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bv131_5 deposited under accession number ATCC 98444;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bv131_5 deposited under accession number ATCC 98444;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bv131_5 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bv131_5 deposited under accession number ATCC 98444;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:10;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

22. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:10;

(b) the amino acid sequence of SEQ ID NO:10 from amino acid 430 to amino acid 564;

(c) fragments of the amino acid sequence of SEQ ID NO:10 comprising eight consecutive amino acids of SEQ ID NO:10; and

(d) the amino acid sequence encoded by the cDNA insert of clone bv131_5 deposited under accession number ATCC 98444;
the protein being substantially free from other mammalian proteins.

23. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:9.

24. An isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 67 to nucleotide 690;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 1 to nucleotide 576;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bv227_1 deposited under accession number ATCC 98444;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bv227_1 deposited under accession number ATCC 98444;
 - (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bv227_1 deposited under accession number ATCC 98444;
 - (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bv227_1 deposited under accession number ATCC 98444;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:12;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
 - (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

25. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- (b) the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 170;

- (c) fragments of the amino acid sequence of SEQ ID NO:12 comprising eight consecutive amino acids of SEQ ID NO:12; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone bv227_1 deposited under accession number ATCC 98444;
- the protein being substantially free from other mammalian proteins.

26. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:11.
27. An isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 657 to nucleotide 1469;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 678 to nucleotide 1103;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cd265_11 deposited under accession number ATCC 98444;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cd265_11 deposited under accession number ATCC 98444;
 - (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cd265_11 deposited under accession number ATCC 98444;
 - (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cd265_11 deposited under accession number ATCC 98444;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:14;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

28. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
 - (b) the amino acid sequence of SEQ ID NO:14 from amino acid 8 to amino acid 149;
 - (c) fragments of the amino acid sequence of SEQ ID NO:14 comprising eight consecutive amino acids of SEQ ID NO:14; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone cd265_11 deposited under accession number ATCC 98444;
- the protein being substantially free from other mammalian proteins.

29. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:13.

30. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 261 to nucleotide 896;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 330 to nucleotide 896;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 1 to nucleotide 515;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ej265_4 deposited under accession number ATCC 98444;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ej265_4 deposited under accession number ATCC 98444;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ej265_4 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ej265_4 deposited under accession number ATCC 98444;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:16;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

31. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:16;

(b) the amino acid sequence of SEQ ID NO:16 from amino acid 1 to amino acid 85;

(c) fragments of the amino acid sequence of SEQ ID NO:16 comprising eight consecutive amino acids of SEQ ID NO:16; and

(d) the amino acid sequence encoded by the cDNA insert of clone ej265_4 deposited under accession number ATCC 98444;

the protein being substantially free from other mammalian proteins.

32. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:15.

33. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 946 to nucleotide 2232;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 1336 to nucleotide 1853;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ey29_8 deposited under accession number ATCC 98444;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ey29_8 deposited under accession number ATCC 98444;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ey29_8 deposited under accession number ATCC 98444;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ey29_8 deposited under accession number ATCC 98444;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:18;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

34. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:18;

(b) the amino acid sequence of SEQ ID NO:18 from amino acid 138 to amino acid 302;

(c) fragments of the amino acid sequence of SEQ ID NO:18 comprising eight consecutive amino acids of SEQ ID NO:18; and

(d) the amino acid sequence encoded by the cDNA insert of clone ey29_8 deposited under accession number ATCC 98444;

the protein being substantially free from other mammalian proteins.

35. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:17.

36. An isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 2588 to nucleotide 3439;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 3005 to nucleotide 3502;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone gm114_10 deposited under accession number ATCC 98444;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone gm114_10 deposited under accession number ATCC 98444;
 - (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone gm114_10 deposited under accession number ATCC 98444;
 - (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone gm114_10 deposited under accession number ATCC 98444;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:20;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
 - (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
37. A protein comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:20;
 - (b) the amino acid sequence of SEQ ID NO:20 from amino acid 145 to amino acid 284;

(c) fragments of the amino acid sequence of SEQ ID NO:20 comprising eight consecutive amino acids of SEQ ID NO:20; and

(d) the amino acid sequence encoded by the cDNA insert of clone gm114_10 deposited under accession number ATCC 98444; the protein being substantially free from other mammalian proteins.

38. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:19.

FIGURE 1A





FIGURE 1B





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/47, A61K 38/17		A3	(11) International Publication Number: WO 98/55614
			(43) International Publication Date: 10 December 1998 (10.12.98)
(21) International Application Number: PCT/US98/11210		(72) Inventors: JACOBS, Kenneth; 151 Beaumont Street, Newton, MA 02160 (US). McCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LAVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US). RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US). SPAULDING, Vikki; 11 Meadowbank Road, Billerica, MA 01821 (US). AGOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US). HOWES, Steven, H.; Apartment 2, 44 Chester Street, Somerville, MA 02144 (US). FECHTEL, Kim; 46 Marion Road, Arlington, MA 02174 (US).	
(22) International Filing Date: 1 June 1998 (01.06.98)		(74) Agent: SPRUNGER, Suzanne, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).	
(30) Priority Data:		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
08/868,899 4 June 1997 (04.06.97) US 08/868,898 4 June 1997 (04.06.97) US 08/869,192 4 June 1997 (04.06.97) US 08/869,191 4 June 1997 (04.06.97) US 08/869,193 4 June 1997 (04.06.97) US 08/868,697 4 June 1997 (04.06.97) US 08/868,698 4 June 1997 (04.06.97) US 08/868,900 4 June 1997 (04.06.97) US 08/868,696 4 June 1997 (04.06.97) US 08/869,194 4 June 1997 (04.06.97) US 09/087,255 29 May 1998 (29.05.98) US		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).		(88) Date of publication of the international search report: 1 April 1999 (01.04.99)	
(54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM			
(57) Abstract			
Polynucleotides and the proteins encoded thereby are disclosed.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JS 98/11210

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 98 25959 A (CHIRON CORP. (US); ESCOBEDO J; HU Q; GARCIA P; WILLIAMS L; KOTHAKOTA S) 18 June 1998</p> <p>see page 3, line 21-24</p> <p>see page 9, line 26-31</p> <p>see page 10, line 24-29</p> <p>see page 18, line 18-23</p> <p>see page 19, line 30 - page 20, line 6</p> <p>see page 20, line 28 - page 21, line 17</p> <p>Seq.ID:15</p> <p>see page 42</p> <p>Seq.ID:34</p> <p>see page 66 - page 68</p> <p>see page 74 - page 77; claims</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-7,10, 11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

13 November 1998

Date of mailing of the international search report

15.02.1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/11210

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 98 45435 A (GENETICS INSTITUTE INC (US); JACOBS; MCCOY; LAVALLIE; RACIE ET AL.) 15 October 1998 see page 56, line 28 - page 57, line 6 Seq.ID:494 see page 259	1-7,9-11
X	--- EP 0 679 716 A (MATSUBARA KENICHI; OKUBO KOUSAKU (JP)) 2 November 1995 cited in the application see page 8, line 20-35 see page 20, line 25-51 Seq.ID:2648 see page 907 - page 908	1,11
X	--- Database EMBL Emest10, Entry HS673190 Accession number R88673 26 August 1995 97% identity with Seq.ID:1 nt.1-338 XP002084310 cited in the application see the whole document	1,11
X	--- Database EMBL Emest9, Entry HS37978 Accession number R15379 22 April 1995 97% identity with Seq.ID:1 nt.326-725 XP002084311 cited in the application see the whole document	1,11
X	--- Database EMBL Emest9, Entry HS273155 Accession number H18273 2 July 1995 98% identity with Seq.ID:1 nt.641-1065 XP002084312 see the whole document	1,11
X	--- Database EMBL Emest7, Entry HS1210943 Accession number AA405257 11 May 1997 99% identity with Seq.ID:1 nt.831-1339 XP002084313 see the whole document	1,11
X	--- Database EMBL Emest11, Entry HS796352 Accession number W56796 8 June 1996 98% identity with Seq.ID:1 nt.1319-1741 reverse orientation XP002084314 see the whole document --- -/--	1,11

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/11210

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 07198 A (GENETICS INSTITUTE INC (US); JACOBS K; MCCOY JM; KELLEHER K; CARLIN M) 27 February 1997 ---	
A	TASHIRO K. ET AL.: "Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins" SCIENCE, vol. 261, 30 July 1993, pages 600-603, XP000673204 ---	
A	YOKOYAMA-KOBAYASHI M. ET AL.: "A signal sequence detection system using secreted protease activity as an indicator" GENE, vol. 163, 1995, pages 193-196, XP002053953 ---	
A	US 5 536 637 A (JACOBS KENNETH; GENETICS INSTITUTE INC. (US)) 16 July 1996 cited in the application -----	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/11210

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-11

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-11

Polynucleotide comprising the nucleotide sequence of Seq.ID:1 and encoding a polypeptide of Seq.ID:2 or fragments. Polynucleotide fragments, variants, homologues, gene thereof. Host cell transformed with said polynucleotide. Protein comprising an amino acid sequence of Seq.ID:2 or fragments thereof. Process for producing said protein.

2. Claims: 12-14

Polynucleotide comprising the nucleotide sequence of Seq.ID:3 and encoding a polypeptide of Seq.ID:4 or fragments. Polynucleotide fragments, variants, homologues, gene thereof. Protein comprising an amino acid sequence of Seq.ID:4 or fragments thereof.

3. Claims: 15-17

As invention 2 but concerning Seq.ID:5 and 6.

4. Claims: 18-20

As invention 2 but concerning Seq.ID:7 and 8.

5. Claims: 21-23

As invention 2 but concerning Seq.ID:9 and 10.

6. Claims: 24-26

As invention 2 but concerning Seq.ID:11 and 12.

7. Claims: 27-29

As invention 2 but concerning Seq.ID:13 and 14.

8. Claims: 30-32

As invention 2 but concerning Seq.ID:15 and 16.

9. Claims: 33-35

As invention 2 but concerning Seq.ID:17 and 18.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. Claims: 36-38

As invention 2 but concerning Seq.ID:19 and 20.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JS 98/11210

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9825959	A	18-06-1998	AU	5796298 A	03-07-1998
WO 9845435	A	15-10-1998	AU	6956698 A	30-10-1998
EP 0679716	A	02-11-1995	AU	8116494 A	13-06-1995
			CA	2153480 A	01-06-1995
			WO	9514772 A	01-06-1995
WO 9707198	A	27-02-1997	US	5707829 A	13-01-1998
			AU	6712396 A	18-02-1997
			AU	6768596 A	12-03-1997
			CA	2227220 A	06-02-1997
			CA	2229208 A	27-02-1997
			EP	0839196 A	06-05-1998
			EP	0851875 A	08-07-1998
			WO	9704097 A	06-02-1997
US 5536637	A	16-07-1996	US	5712116 A	27-01-1998

THIS PAGE BLANK (USPTO)